

10/ 507,399

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the
IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 13 JAN 30 Saved answer limit increased
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
added to TULSA
NEWS 15 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
visualization results
NEWS 16 FEB 22 Status of current WO (PCT) information on STN
NEWS 17 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 18 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 19 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 20 FEB 28 MEDLINE/LMEDLINE reload improves functionality
NEWS 21 FEB 28 TOXCENTER reloaded with enhancements
NEWS 22 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral
property data
NEWS 23 MAR 01 INSPEC reloaded and enhanced
NEWS 24 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

10/ 507,399

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:04:47 ON 07 MAR 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:04:53 ON 07 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2006 HIGHEST RN 876011-49-3

DICTIONARY FILE UPDATES: 6 MAR 2006 HIGHEST RN 876011-49-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*



Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10507399.str



```

chain nodes :
11 12 13
ring nodes :
1 2 3 4 5 6 7 8 9 10 14 15 16 17 18 19
chain bonds :
7-11 9-12 12-13 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 14-15 14-19 15-16 16-17
17-18 18-19
exact/norm bonds :
4-7 5-10 7-8 7-11 8-9 9-10 12-13 13-14
exact bonds :
9-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19
isolated ring systems :
containing 1 : 14 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sample

10/ 507,399

SAMPLE SEARCH INITIATED 16:05:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 126 TO ITERATE

100.0% PROCESSED 126 ITERATIONS 34 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1847 TO 3193
PROJECTED ANSWERS: 331 TO 1029

L2 34 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 16:05:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2464 TO ITERATE

100.0% PROCESSED 2464 ITERATIONS 758 ANSWERS
SEARCH TIME: 00.00.01

L3 758 SEA SSS FUL L1

=> s thiazolid?

L4 204946 THIAZOLID?

=> s l3 and l4

L5 13 L3 AND L4

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.14	172.35

FILE 'HCAPLUS' ENTERED AT 16:06:05 ON 07 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Mar 2006 VOL 144 ISS 11
FILE LAST UPDATED: 6 Mar 2006 (20060306/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 16:04:47 ON 07 MAR 2006)

10/ 507,399

FILE 'REGISTRY' ENTERED AT 16:04:53 ON 07 MAR 2006

L1 STRUCTURE UPLOADED

L2 34 S L1 SAMPLE

L3 758 S L1 FULL

L4 204946 S THIAZOLID?

L5 13 S L3 AND L4

FILE 'HCAPLUS' ENTERED AT 16:06:05 ON 07 MAR 2006

=> s 15

L6 60 L5

=> d 16 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 60 ANSWERS - CONTINUE? Y/(N):y

L6 ANSWER 1 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:119938 HCAPLUS
 TITLE: Preparation of human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
 INVENTOR(S): Ewing, William R.; Mapelli, Claudio; Sulsky, Richard B.; Haque, Tasir S.; Lee, Ving G.; Rieksinger, Douglas James; Martinez, Rogelio L.; Zhu, Yeheng
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 236 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006014287	A1	20060209	WO 2005-US23076	20050630
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:		US 2004-585358P P 20040702 US 2005-684805P P 20050526		

AB The invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11 [Xaa1-Xaa3, Xaa5-Xaa11 are (certain) naturally or non-naturally occurring amino acid residues; Xaa4 is glycine] that have biol. activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The novel, chemical modified peptides not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. Peptides of the invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes. Thus, claimed peptide H-H-Aib-EGT-L- α -MePhe(2-fluoro)-TSD-Bip(2'-Et-4'-OMe)-4-(2'-methylphenyl)-3-pyridylalanine-NH₂ (H, E, G, T, S and D are one-letter amino acid symbols, Aib = α -aminoisobutyric acid residue, Bip = biphenylalanine residue) was prepared by the solid-phase method and shown to produce a time-dependent statistically significant decrease in postprandial plasma glucose following s.c. administration in ob/ob mice.
 IT 199113-98-9, NN-2344
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (preparation of human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions)
 RN 199113-98-9 HCAPLUS

L6 ANSWER 2 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:33751 HCAPLUS
 DOCUMENT NUMBER: 144:128966
 TITLE: Constrained cyano compounds as selective inhibitors of dipeptidyl peptidase IV, their preparation, pharmaceutical compositions, and use in therapy
 INVENTOR(S): Campbell, David Alan; Betancort, Juan Manuel; Winn, David T.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 35 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006009518	A1	20060112	US 2005-179797	20050712
WO 2006017292	A1	20060216	WO 2005-US24695	20050712
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:		US 2004-587391P P 20040712		

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to constrained cyano compds. of formula I, which are selective inhibitors of dipeptidyl peptidase IV (DPP-IV). In compds. I, X is (un)substituted C, optionally forming a double bond with one of the carbon atoms to which it is attached, S, or O; R1 and R4 are independently H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted cycloalkyl-alkyl, (un)substituted aryl, (un)substituted aralkyl, etc.; and R2, R3, R5, and R6 are independently selected from H, F, Cl, Br, I, OH, NH₂, CN, alkoxy, (di)alkylamino, acyl, alkoxycarbonyl, aryloxy, etc. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I together with at least one pharmaceutically acceptable carrier or diluent, optionally in combination with another active ingredient, as well as to the use of the compns. for treating, controlling, or preventing conditions affected by dipeptidyl peptidase-IV inhibition. Esterification of (S)-phenylglycine followed by condensation with benzaldehyde, α -allylation, hydrolysis and N-protection gave amino acid II, which underwent ozonolysis, ester hydrolysis, and cyclization with L-cysteine Me ester to give thiazolidine III. Intramol. cyclocondensation of III, amidation, dehydration and deprotection resulted in the formation of hexahydropyridothiazole IV. The compds. of the invention are selective

L6 ANSWER 1 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 for DPP-IV over other dipeptidyl peptidases with compd. IV being more than 100-fold selective for DPP-IV over DPP-VII, DPP-VIII, and fibroblast activation protein (FAP) and between 10- and 100-fold for DPP-IV over DPP-IX.
 IT 199113-98-9, NN-2344
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (preparation of constrained cyano compds. as selective inhibitors of dipeptidyl peptidase IV)
 RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 3 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:30433 HCAPLUS
DOCUMENT NUMBER: 144:135217
TITLE: Pharmaceutical compositions containing bezafibrate and analogs and diflunisal and its analog for the treatment of metabolic disorders
INVENTOR(S): Lee, Margaret S.; Zimmerman, Grant R.; Finelli, Alyce Lynn; Grau, Daniel; Keith, Curtis; Nichols, M. James
PATENT ASSIGNEE(S): Combinatorm, Incorporated, USA
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006004803	A1	20060112	WO 2005-US23030	20050629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GU, HT, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

PRIORITY APPLN. INFO.: US 2004-584380P P 20040630
US 2005-649329P P 20050202

AB The invention features compns., methods, and kits for the treatment of metabolic disorders such as diabetes and obesity. For example, an oral composition containing combination of bezafibrate and diflunisal was found to be


able to significantly increased the insulin-stimulated glucose uptake.

IT 199113-98-9, Balaglitazone

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing bezafibrate and analogs and diflunisal analogs or cinnamic acid for treatment of metabolic disorders)

RN 199113-98-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:15809 HCAPLUS
DOCUMENT NUMBER: 144:94418
TITLE: A pharmaceutical formulation of balaglitazone
INVENTOR(S): Ravn, Carsten; Rasmussen, Stella Rudkær
PATENT ASSIGNEE(S): Dr. Reddy's Laboratories Ltd., India; Dr. Reddy's Laboratories, Inc.
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006002255	A2	20060105	WO 2005-US22094	20050622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GU, HT, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

PRIORITY APPLN. INFO.: DK 2004-977 A 20040623


AB A formulation of 5-[[4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)methoxy]benzyl]thiazolidine-2,4-dione (balaglitazone) and/or pharmaceutically acceptable salts thereof is provided.

IT 199114-17-5

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulation of balaglitazone)

RN 199114-17-5 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-, potassium salt (9CI) (CA INDEX NAME)




• X

IT 199113-98-9, Balaglitazone

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmaceutical formulation of balaglitazone)

L6 ANSWER 3 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 4 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 199113-98-9 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1075657 HCAPLUS
DOCUMENT NUMBER: 143:353392
TITLE: Therapeutic agent for diabetes containing insulin resistance improving agent
INVENTOR(S): Kanda, Shoichi; Araki, Kazushi
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan; Ohsumi, Jun
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092382	A1	20051006	WO 2005-JP5526	20050325
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2005314380	A2	20051110	JP 2005-88634	20050325
PRIORITY APPLN. INFO.: JP 2004-94598 A 20040329				
AB Disclosed is a therapeutic method for diseases that maintains excellent medicinal effects, suppressing any side effects (for example, edema or the like) to thereby ensure high safety. There is provided a pharmaceutical composition comprising an insulin resistance improving agent as an active ingredient, characterized in that an administration cycle of insulin resistance improving agent wherein the dosage thereof is reduced or discontinued during the administration period is repeated at least once.				
199113-98-9, NN-2344				
IT RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (therapeutic agents for diabetes containing insulin resistance improving agents for use by specified method)				
RN 199113-98-9 HCAPLUS				
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)				



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:732644 HCAPLUS
DOCUMENT NUMBER: 143:211899
TITLE: Preparation of heterocyclic bicyclooctylcarboxamide derivatives as modulators of glucocorticoid receptor, AP-1, and/or NF-κB
INVENTOR(S): Weinstein, David S.; Sheppeck, James; Gilmore, John L.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005073221	A1	20050811	WO 2005-US1293	20050114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005182083	A1	20050818	US 2005-35290	20050113
PRIORITY APPLN. INFO.: US 2004-537048P P 20040116				
OTHER SOURCE(S): MARPAT 143:211899				
GI US 2005-35290 A 20050113				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [Y and W independently = C or N; X = CR3R4; R = H, alkyl, aryl, etc.; R1 = H, halo, alkenyl, etc.; R2 = H, alkoxy, aryloxy, etc.; R3 and R4 independently = H, alkenyl, alkoxy, etc. or R3 and R4 may optionally be taken together with the carbon that they are attached to form a 3-7 membered ring which may optionally include an O or N atom; Z = CONSR6, CH2NRS6, SONRS6, etc.; R5 and R6 independently = H, amino, heteroaryl, etc.; one of A and B = (un)substituted heterocycle and the other = (un)substituted carbocycle or heterocycle with provisions] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of glucocorticoid receptor, AP-1, and/or NF-κB. Thus, e.g., II was prepared by amidation of III (preparation given) with 4-(4-fluorophthalen-1-yl)-thiazol-2-ylamine. The activity of I to inhibit AP-1 was evaluated using cellular transrepression assays and it was revealed that compds. of the invention possessed an EC50 value of less than 15 nM. I as modulator of glucocorticoid receptor, AP-1, and/or NF-κB should prove useful in the treatment of obesity, diabetes and inflammatory or immune associated diseases. Pharmaceutical compns. comprising I are disclosed.

IT 199113-98-9, NN-2344
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed co-drugs; preparation of heterocyclic bicyclooctylcarboxamide

L6 ANSWER 5 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L6 ANSWER 6 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
derivs. as modulators of glucocorticoid receptor, AP-1, and/or NF-κB

RN 199113-98-9 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2005:732629 HCAPLUS

DOCUMENT NUMBER: 143:211898

TITLE: Preparation of heterocyclic bicyclooctylcarboxamide derivatives as modulators of glucocorticoid receptor, AP-1, and/or NF- κ B

INVENTOR(S): Yang, Bingwei Vera

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005073203	A1	20050811	WO 2005-US1794	20050114
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			


US 2005176749 A1 20050811 US 2005-34635 20050113

PRIORITY APPL. INFO.: US 2004-537468P P 20040116

OTHER SOURCE(S): MARPAT 143:211898

GI

L6 ANSWER 7 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB Title compds. I [X = C5R5R6; R = H, alkyl, aryl, etc.; R1 and R2 independently = H, alkynyl, cycloalkyl, etc. or R1 and R2 together with the N atom that they are attached to can form 5-7 membered heteroaryl or cycloheteroalkyl ring which contains 1-3 heteroatoms selected from N, O or S; R3 = H, halo, OH, etc.; R4 = H, alkenyl, alkoxy, etc.; R5 and R6 independently = H, CN, aryl, etc. or R5 and R6 may optionally be taken together with the carbon that they are attached to form a 3-7 membered ring which may optionally include an O or N atom; A and B independently = (un)saturated 6-membered carbocyclic or heterocyclic ring; Z = S, O or NH] and

their pharmaceutically acceptable salts, are prepared and disclosed as modulators of glucocorticoid receptor, AP-1, and/or NF- κ B. Thus, e.g., II was prepared by Diels-Alder reaction of anthracene with methacrylic acid followed by amidation with Et 2-amino-4-thiazole glyoxylate and subsequent hydrolysis/chlorination/coupling sequence with 1-(2-pyridinyl)piperazine. The activity of I to inhibit AP-1 was evaluated using cellular transrepression assays and it was revealed that compds. of the invention possessed an EC50 value of less than 15 μ M. I as modulator of glucocorticoid receptor, AP-1, and/or NF- κ B should prove useful in the treatment of obesity, diabetes and inflammatory or immune associated diseases. Pharmaceutical compns. comprising I are disclosed.


IT 199113-98-9, NN-2344

AL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (claimed co-drugs; preparation of heterocyclic bicyclooctylcarboxamide derivs. as modulators of glucocorticoid receptor, AP-1, and/or NF- κ B)

RN 199113-98-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 7 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2005:732507 HCAPLUS

DOCUMENT NUMBER: 143:211915

TITLE: Preparation of azolylamino benzobicyclooctanecarboxamides as modulators of activator protein-1 (AP-1) and/or NF- κ B activity.

INVENTOR(S): Weinstein, David S.; Yang, Bingwei Vera; Kim, Soong-Hoon; Vaccaro, Wayne; Sheppeck, James; Gilmore, John

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 149 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005072132	A2	20050811	WO 2005-US1180	20050114
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005187242	A1	20050825	US 2005-35176	20050113
PRIORITY APPL. INFO.:			US 2004-537469P	P 20040116
			US 2005-35176	A 20050113


OTHER SOURCE(S): MARPAT 143:211915

GI





AB Title compds. [I; dotted line = optional double bond; m, n = 1, 2; J, K = C, N, O, S; R = H, alkyl, alkenyl, alkynyl, alkoxy, cyano, aryl, aryloxy, heteroaryl, amino, etc.; R1 = H, halo, alkyl, alkenyl, alkynyl, cyano, cyanoalkyl, hydroxyaryl, NO2, amino, aryl, heteroaryl, etc.; R2 = H, alkyl, alkenyl, alkynyl, alkoxy, aryl, aryloxy, cyano, halo, NO2, cyanoalkyl, etc.; R3, R4 = H, alkyl, alkenyl, alkynyl, aryl, OH, heteroaryl, hydroxyaryl, aryloxyalkyl, etc.; R3R4 = atoms to form a 3-7

L6 ANSWER 8 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 membered ring; R5, R6 = H, halo, OH, alkyl, alkenyl, alkynyl, alkoxy,
 aryl, aralkyl, aryloxy, heteroaryl, cyano, cyanoalkyl, NO2, amino, etc.; B
 = (substituted) carbocyclic, heterocyclic, were prepd. Thus, title
 compd. (II) was prepd. in 21% yield via coupling of the corresponding
 bicyclooctanecarboxylic acid and thiazolylamine in the presence of
 HOAt/EDC/Et3N in MeCN at 85° for 5 h. I have glucocorticoid
 receptor/dexamethasone inhibition activity (>95% at 10 µM) and/or AP-1
 inhibition activity (EC50 <15 µM).
 IT 199113-98-9, NN-2344
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (coadministration; preparation of azolylamino
 benzopyridobicyclooctanecarboxamides
 as modulators of AP-1 and/or NF-κB activity)
 RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-
 quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 9 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2005:729531 HCAPLUS
 DOCUMENT NUMBER: 143:211914
 TITLE: Preparation of azolylamino
 benzopyridobicyclooctanecarboxamides and
 dipyrindobicyclooctanecarboxamides as modulators of
 activator protein 1 (AP-1) and/or NF-κB
 activity.
 INVENTOR(S): Duan, Jingwu; Sheppeck, James; Jiang, Bin; Gilmore,
 John
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 92 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005072732	A1	20050811	WO 2005-US1181	20050114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005182082	A1	20050818	US 2005-34822	20050113
PRIORITY APPLN. INFO.:			US 2004-537437P	P 20040116
			US 2005-34822	A 20050113
OTHER SOURCE(S):		MARPAT 143:211914		
GI				



AB Title compds. [I: R = H, OH, alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, etc.; R1, R2 = H, halo, OH, alkyl, alkenyl, alkynyl, aryl, aryloxy, heteroaryl, cyano, hydroxyaryl, hydroxyalkyl, etc.; R3, R4 = H, alkyl, alkenyl, alkynyl, alkoxy, amino, aryl, OH,

L6 ANSWER 9 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 aryloxy, heteroaryl, etc.; Z = (substituted) aminomethyl, aminocarbonyl, aminosulfonyl, aminosulfinyl; dotted lines = optional double bonds; X1-X8 = CR15, CR16R17, N, NR18; R15-R17 = H, halo, OH, alkyl, alkenyl, alkynyl, alkoxy, aryl, aryloxy, heteroaryl, cyano, CO2H, CH2OH, etc.; R16R17 = O; R18 = H, aryl, alkyl, alkenyl, alkynyl, alkoxy, amino, heteroaryl, cycloalkyl, etc.; with proviso(s), were prepd. Thus, title compd. (II) was prepd. in 7% yield via coupling of the corresponding acid and amine using EDC/HOBT/DIEPA in MeCN at 70° for 17 h. I showed glucocorticoid receptor/dexamethasone inhibition activity (>95% at 10 µM) and/or AP-1 inhibitory activity (EC50 <15 µM).
 IT 199113-98-9, NN-2344
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination therapy; preparation of azolylamino
 benzopyridobicyclooctanecarboxamides and dipyrindobicyclooctanecarboxamides as modulators of AP-1 and/or NF-κB activity)
 RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-
 quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 10 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2005:729529 HCAPLUS
 DOCUMENT NUMBER: 143:211913
 TITLE: Preparation of bis(aryl)tricyclic modulators of
 glucocorticoid receptor, AP-1, and/or NFκB
 activity.
 INVENTOR(S): Yang, Bingwei Vera
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 87 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005072729	A1	20050811	WO 2005-US1229	20050114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005182110	A1	20050818	US 2005-35119	20050113
PRIORITY APPLN. INFO.:			US 2004-537470P	P 20040116
OTHER SOURCE(S):		MARPAT 143:211913		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R = H, alk(en/yn)yl, cycloalkyl, etc.; R' = H, alk(en/yn)yl, cycloalkyl, etc.; R1-2 = H, halo, OH, etc.; R3-4 = H, alkyl, alk(en/yn)yl, alkoxy, etc.; Z = SO1-2-amino, carboxamido, etc.; A, B = (un)saturated 6-membered carbocyclic, heterocyclic ring] are prepared For instance II is prepared in several steps from 9-nitroanthracene, Me 2-acetamidocacrylate and 2-amino-4-(naphthalen-1-yl)imidazole. I are glucocorticoid receptor modulators and are useful for the treatment of diseases associated with AP-1 or NF-κB-induced transcription [no data].
 IT 199113-98-9, NN-2344
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination pharmaceutical; preparation of bis(aryl)tricyclic imidazole/thiazole derivative modulators of glucocorticoid receptor, AP-1, and/or NFκB activity)
 RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:696690 HCAPLUS
DOCUMENT NUMBER: 143:186790
TITLE: Fused aryl and heteroaryl bicyclo[2.2.2]octane derivative modulators of the glucocorticoid receptor, AP-1, and/or NF- κ B activity, and therapeutic use thereof
INVENTOR(S): Duan, Jingwu; Jiang, Bin; Sheppeck, James; Gilmore, John L.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070207	A1	20050804	WO 2005-US1411	20050114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005176716	A1	20050811	US 2005-34652	20050113
PRIORITY APPLN. INFO.: US 2004-537467P P 20040116 US 2005-34652 A 20050113				
OTHER SOURCE(S): MARPAT 143:186790				
GI				




AB A class of non-steroidal compds. are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF- κ B activity including obesity, diabetes, inflammatory and immune diseases. The compds. of the invention are fused aryl and heteroaryl bicyclo[2.2.2]octane derivs. I [R = H, OH, alkyl, etc.; Ra, Rb,

L6 ANSWER 11 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

= H, halo, OH, alkyl, etc.; Rc, Rd = H, alkyl, alkenyl, etc.; Z = S(O)NR₁R₂, CONR₁R₂, CH₂NR₁R₂; t = 1,2; R₁, R₂ = H, alkyl, etc.; X₁-X₈ = CR₁₅, NR₁₈, etc.; R₁₅ = H, halo, OH, etc.; R₁₈ = H, aryl, alkyl, etc.]. Also provided are pharmaceutical compns. and methods comprising the above compds. for treating obesity, diabetes and inflammatory or immune-assocd. diseases. Compd. prepn. is included.

IT 199113-98-9, NN-2344
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fused aryl and heteroaryl bicyclo[2.2.2]octane derivative modulators of glucocorticoid receptor, AP-1, and/or NF- κ B activity, and therapeutic use)
RN 199113-98-9 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2005:612299 HCAPLUS
DOCUMENT NUMBER: 143:133380
TITLE: Preparation of azabicyclic heterocycles as cannabinoid receptor modulators
INVENTOR(S): Gu, Guikue; Ewing, William R.; Mikkilineni, Amarendra B.; Pandri, Annapurna; Ellsworth, Bruce A.; Sher, Philip M.; Gerritz, Samuel; Sun, Chongqing; Murugesan, Natesan; Wu, Ximao
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063762	A1	20050714	WO 2004-US42878	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005171110	A1	20050804	US 2004-16198	20041217
PRIORITY APPLN. INFO.: US 2003-531451P P 20031219 US 2004-16198 A 20041217				
OTHER SOURCE(S): MARPAT 143:133380				
GI				



AB The present application describes compds. I [R₁, R₂ = halo, CN, alkyl, etc.; R₃ = H, alkyl, alkenyl, cycloalkyl, etc.; R₄ is absent when n is a double bond; R₄ = H, alkyl, cycloalkyl, etc.; R₅ = halo, (un)substituted OH, NH₂, etc. when m is a single bond; R₅ = O when m = a double bond; m, n = a single or double bond; when m is a single bond, n is a double bond; when m is a double bond, n is a single bond], pharmaceutical compns. comprising at least one compound I and optionally one or more addnl. therapeutic agents and methods of treatment using the compds. I both alone

L6 ANSWER 12 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
and in combination with one or more addnl. therapeutic agents. Over 40
comps. I were prep'd. E.g., a multi-step synthesis of II, starting from
dichloromandelic anhydride, was given. The exemplified compds. I showed
the CB-1 receptor binding Ki values in the range of 0.01 nM to 10000 nM.
199113-98-9
IT RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-drug; preparation of azabicyclic heterocycles as cannabinoid receptor
modulators)
RN 199113-98-9 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-
quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 13 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:572592 HCAPLUS
DOCUMENT NUMBER: 143:97378
TITLE: Preparation of azabicyclic heterocycles as cannabinoid
receptor modulators
INVENTOR(S): Yu, Guixue; Ewing, William R.; Mikkilineni, Amarendra
B.; Pandri, Annapurna; Sher, Philip M.; Gerritz,
Samuel; Ellsworth, Bruce A.; Wu, Gang; Huang, Yanting;
Sun, Chongqing; Murugesan, Natesan; Gu, Zhengxiang;
Wang, Ying; Sitkoff, Dorree; Johnson, Stephen R.; Wu,
Ximao
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 196 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005143381	A1	20050630	US 2004-16135	20041217
WO 2005063761	A1	20050714	WO 2004-0542820	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005192278	A1	20050901	US 2004-15876	20041217
WO 2005061509	A1	20050707	WO 2004-0542542	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPL. INFO.:		US 2003-531451P		P 20031219
		US 2004-16135		A 20041217
OTHER SOURCE(S):		MARPAT 143:97378		
GI				

L6 ANSWER 13 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The present application describes compds. I [R1, R2 = halo, CN, alkyl,
etc.; R3 = alkyl, alkenyl, cycloalkyl, etc.; R6 = H, alkyl, cycloalkyl,
etc.; R7 is absent when double bond; or R7 = H, alkyl, cycloalkyl, etc.],
pharmaceutical compds. comprising at least one compound I and optionally one
or more addnl. therapeutic agents and methods of treatment using the
compds. I both alone and in combination with one or more addnl.
therapeutic agents. Over 400 compds. I were prepared E.g., a multi-step
synthesis of II, starting from dibromopyridazine, was given.
Representative compds. I showed the CB-1 receptor binding Ki values in the
range of 0.01 nM to 10000 nM.
199113-98-9, NN-2344
IT RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-drug; preparation of azabicyclic heterocycles as cannabinoid receptor
modulators)
RN 199113-98-9 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-
quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 14 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:493507 HCAPLUS
DOCUMENT NUMBER: 143:43869
TITLE: Preparation of nitrogen containing bicyclic
pyridine-based derivatives as inhibitors of HMG CoA
reductase
INVENTOR(S): O'Connor, Stephen P.; Robl, Jeffrey; Ahmad, Saleem;
Bisaha, Sharon; Murugesan, Natesan; Ngu, Khehyong;
Shi, Yan; Stein, Philip D.; Soundararajan, Nachimuthu;
Natalie, Kenneth J., Jr.; Kolla, Lakma R.; Sausker,
Justin; Quinlan, Sandra L.; Fan, Junying; Petsch,
Dejash; Guo, Zhenrong
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051386	A1	20050609	WO 2004-0539051	20041119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005171140	A1	20050804	US 2004-989138	20041115
PRIORITY APPL. INFO.:		US 2003-523546P		P 20031120
		US 2004-989138		A 20041115
OTHER SOURCE(S):		MARPAT 143:43869		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Het = 5- to 8-membered ring including at least one
nitrogen atom with provisions; n = 0-1; R1 and R2 independently = H,
alkyl, alkenyl, etc.; R3 = H, aryl, cycloalkyl, etc.; R4 and R5
independently = H, alkyl; X = -CR6R7-CR6aR7a-, -CR6=CR7-, R6, R7, R6a and
R7a independently = H, alkyl] and their pharmaceutically acceptable salts,
are prepared and disclosed as inhibitors of HMG CoA reductase. Thus, e.g.,
II was prepared by cyclization of Et 2-amino-4-(4-fluorophenyl)-6-isopropyl-
5-methoxycarbonyl-3-pyridinepropanoate (preparation given) followed by a
reduction/sulfonylation/reduction sequence to give
[4-(4-fluorophenyl)-2-isopropyl-
8-methanesulfonyl-5,6,7,8-tetrahydro[1,8]naphthyridin-3-yl]-methanol
(III). III was oxidized to the resp. aldehyde and coupled with
1,1-dimethylethyl(4R,6S)-2,2-dimethyl-6-(1-phenyl-1H-tetrazole-5-
sulfonylmethyl)-[1,3]dioxan-4-yl-acetate followed by ring opening to give
II. I should display activity as inhibitors of HMG CoA reductase (no data
given). I as inhibitors of HMG CoA reductase inhibitors should prove

L6 ANSWER 14 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 useful in the treatment of, but not limited to, hyperlipidemia,
 dyslipidemia, and atherosclerosis. Pharmaceutical compns. comprising I
 are disclosed.
 IT 199113-98-9, Nn-2344
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (claimed co-drug; preparation of nitrogen-containing bicyclic
 pyridine-based
 derivs. as inhibitors of HMG CoA reductase)
 RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-
 quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:451240 HCAPLUS
 DOCUMENT NUMBER: 142:457108
 TITLE: Method of identifying responders to treatment with
 insulin sensitizers by measuring the ratio of HMW
 adiponectin to total or LMW adiponectin
 INVENTOR(S): Wagner, John A.; Scherer, Philipp E.; Pajvani, Utpal
 B.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Albert Einstein College of
 Medicine of Yeshiva University
 SOURCE: PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046734	A1	20050526	WO 2004-US36648	20041104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-518390F P 20031107
 AB A patient who is a responder to a therapeutic treatment for insulin
 resistance or for one or more diseases associated with type 2 diabetes can
 be

identified by the method of measuring the amount of HMW adiponectin and the
 amount of total adiponectin or LMW adiponectin in the patient's tissue
 (usually plasma or serum) before the therapeutic treatment commences; then
 commencing the therapeutic treatment; and finally measuring the amount of
 HMW adiponectin and the amount of either total adiponectin or LMW
 adiponectin in the patient's plasma or serum one or more times after
 commencement of the therapeutic treatment. The patient is predicted to be
 a responder to the therapeutic treatment if the ratio of the amount of HMW
 adiponectin to the amount of total adiponectin or LMW adiponectin increases
 after the therapeutic treatment commences.

IT 199113-98-9, Balaglitazone
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (method of identifying responders to treatment with insulin sensitizers
 by measuring the ratio of HMW adiponectin to total or LMW adiponectin)
 RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-
 quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 15 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 16 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:395091 HCAPLUS
 DOCUMENT NUMBER: 142:423901
 TITLE: Therapeutic agent for keratoconjunctiva disorder
 INVENTOR(S): Nakamura, Masatugu Hirai, Shinshiro
 PATENT ASSIGNEE(S): Santen Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 19 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039571	A1	20050506	WO 2004-JP16460	20041029
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

JP 2005162735 A2 20050623 JP 2004-314901 20041029
 PRIORITY APPLN. INFO.: JP 2003-368548 A 20031029
 JP 2003-379801 A 20031110

AB New medicinal uses of 5-[[4-[[3-methyl-4-oxo-3,4-dihydro-2-
 quinazolinyl)methoxy]phenyl]methyl]thiazolidine-2,4-dione and
 N-[[4-methoxyphenoxy]carbonyl]-N-[[4-[[2-(5-methyl-2-phenyl-4-
 oxazolyl)ethoxy]phenyl]methyl]glycine were studied. The compds. each has
 an excellent ameliorative effect on corneal disorder models and is useful
 in treatments for keratoconjunctiva disorders such as dry eye, corneal
 ulcer, conjunctivitis, conjunctivitis, superficial punctate keratopathy,
 subepithelial corneal defects, subepithelial conjunctival defects,
 keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, and
 filamentous keratitis.

IT 199113-98-9, 5-[[4-[[3-Methyl-4-oxo-3,4-dihydro-2-
 quinazolinyl)methoxy]phenyl]methyl]thiazolidine-2,4-dione
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical
 process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological
 study); PROC (Process); USES (Uses)
 (therapeutic agent for keratoconjunctiva disorder)
 RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-
 quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS

L6 ANSWER 16 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 17 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:300435 HCAPLUS
DOCUMENT NUMBER: 142:373859
TITLE: Preparation of pyrimidine and pyridine derivatives
useful as HMG-CoA reductase inhibitors
INVENTOR(S): Ahmad, Saleem; Robl, Jeffrey A.; Ngu, Khehyong
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030758	A1	20050407	WO 2004-US31212	20040922
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GM, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005085497	A1	20050421	US 2004-946055	20040921
PRIORITY APPL. INFO.:			US 2003-505893P	P 20030925
OTHER SOURCE(S):	MARPAT	142:373859		

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = N, CR5; R1-2 = H, alkyl, alkoxyalkyl, etc.; R3 = (hetero)aryl, cycloalkyl, etc.; R4 = H, (cyclo)alkyl, haloalkyl, etc.; R5 = H, alkyl; Z = hydroxyalkyl, etc.] are prepared For instance, II is prepared in 5 steps from a substituted pyrimidine, 2-methyl-2H-[1,2,4]triazol-3-ylamine, and a prior art homochiral dihydroxy acetone derivative I are HMG-CoA reductase inhibitors and are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis [no data].
IT 199113-98-9, NN-2344
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of pyrimidine and pyridine derivs.
useful as HMG-CoA reductase inhibitors)
RN 199113-98-9 HCAPLUS

L6 ANSWER 17 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:14212 HCAPLUS
DOCUMENT NUMBER: 142:107414
TITLE: Compositions comprising balaglitazone and further antidiabetic compounds
INVENTOR(S): Wassermann, Karsten; Wulff, Erik Max
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000299	A1	20050106	WO 2004-DK448	20040624
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2530228	AA	20050106	CA 2004-2530228	20040624
PRIORITY APPL. INFO.:			DK 2003-973	A 20030627
			US 2003-483196P	P 20030627
			WO 2004-DK448	W 20040624

AB Methods for the treatment of type 2 diabetes and related conditions comprising the administration of balaglitazone in combination with one or more other antidiabetic compound is provided together with combinations useful in said treatment.
IT 199113-98-9, Balaglitazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising balaglitazone and further antidiabetic compds.)
RN 199113-98-9 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1127349 HCAPLUS

DOCUMENT NUMBER: 142:74574

TITLE: Preparation of 1,2,4-triazolylethylamines as modulators of the glucocorticoid receptor
 INVENTOR(S): Robinson, Leslie; Rueter, Jaimie K.; Moree, Wilna J.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 69 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004111015	A1	20041223	WO 2004-US18487	20040611
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004266831	A1	20041230	US 2004-865443	20040610
PRIORITY APPL. INFO.:			US 2003-477545P	P 20030611
OTHER SOURCE(S):	MARPAT 142:74574			

GI



L6 ANSWER 20 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1124594 HCAPLUS

DOCUMENT NUMBER: 142:79882

TITLE: Non-steroidal compound modulators of the glucocorticoid receptor and therapeutic uses for glucocorticoid receptor agonist or antagonist dependent diseases

INVENTOR(S): Hadida-Ruah, Sara Sabine; He, Xiaohui; Nagasawa, Johnny Yasuo

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110385	A2	20041223	WO 2004-US18677	20040611
WO 2004110385	A3	20050127		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004266758	A1	20041230	US 2004-865444	20040610
PRIORITY APPL. INFO.:			US 2003-477574P	P 20030611
OTHER SOURCE(S):	MARPAT 142:79882			

GI



AB The present invention relates to new non-steroidal compds. which are glucocorticoid receptor (GR) modulators (that is agonists and antagonists) and thus are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes and inflammatory or immune associated diseases, and to a method for using such compds. to treat these and related diseases. Specifically, the novel non-steroidal compds. have the structure as formula (I), wherein R1 through R6 are independently (i) hydrogen, F, Cl, Br, I, NO2, CN, or OR10, etc. (ii)

L6 ANSWER 19 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


AB Title compds. I [A, B = cycloalkyl, aryl, heteroaryl; R1 = H, acyl, carboxy, etc.; R2-4 = H, alkyl, heteroalkyl, etc.; R5-6 = H, F, Cl, Br, etc.] are prepared General synthetic procedures are provided for the synthesis of 19 examples, e.g., II. Example compds. are tested in a glucocorticoid receptor binding assay in the range of 0.1 nM to 40 μM [no data]. I are glucocorticoid receptor modulators and are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, inflammatory and immune disorders.

IT 199113-98-9, NN-2344

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination pharmaceutical; preparation of 1,2,4-triazolylethylamines as modulators of glucocorticoid receptor)

RN 199113-98-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


C1-6-alkyl, C3-8-cycloalkyl, or C2-6-alkenyl, etc; R7 is hydrogen, C1-6-alkyl, or C3-8-cycloalkyl, etc; R8 and R9 are independently hydrogen, C1-6-alkyl, or C3-8-cycloalkyl, etc; Y is O, S, or NR14; Z is O, S, S(O), S(O)2, or NR15; and X is OCR16R17, SCR16R17, S(O)CR16R17, etc.

IT 199113-98-9, NN 2344

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (non-steroidal compound modulators of glucocorticoid receptor and therapeutic uses for glucocorticoid receptor agonist or antagonist-dependent diseases)

RN 199113-98-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 21 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2004:755468 HCAPLUS

DOCUMENT NUMBER: 141:370686

TITLE: Generic, highly selective and robust capillary electrophoresis method for separation of a racemic mixture of glitazone compounds

AUTHOR(S): Jamali, Babak; Theill, Gitta Cargen; Sorensen, Lise-Lotte

CORPORATE SOURCE: Department of Analytical Development, CMC Development, Global Development, Novo Nordisk A/S, Maaloev, DK-2760, Den

SOURCE: Journal of Chromatography, A (2004), 1049(1-2), 183-187

CODEN: JCRAYE; ISSN: 0021-9673

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A generic, highly selective, and robust capillary electrophoresis (CE) method was developed for separation of a racemic mixture of three available glitazone compds. (also known as thiazolidinediones) in active pharmaceutical ingredients (API) and tablets. The method separated the R and

and S enantiomers of balaglitazone, pioglitazone and rosiglitazone, and showed that the samples contained an equal (50:50) quantity of the enantiomers as a mixture. After a simple extraction of samples with acetonitrile:water (80:20),

separation was performed using a combination of two cyclodextrins:

sulfobutylether- β -cyclodextrin (SB- β -CD) and

dimethyl- β -cyclodextrin (DM- β -CD) in the electrolyte at pH 8.0.

The method showed a very good specificity, and all sepns. were achieved

with a resolution (R_s) over 3.0. The developed CE method was then

validated.

The R_s for the sepns. were 3.5 for balaglitazone enantiomers, 3.5 for pioglitazone enantiomers, and 3.7 for rosiglitazone. The squared correlation coeffs. (r^2) were found to be 0.999 for all three compds. The range of the CE method (injection volume was approx. 4 nl) was demonstrated to be from 1.0 to 2.4 ng. The R.S.D. in the repeatability study was found to be less than 0.5 for area/area ratio (and 3.0% for area) for all three

compds. The R.S.D. in the intermediate precision study was found to be less than 0.7 for area/area ratio (and 4.5% for area) for all three compds. Generally, the method showed good robustness. Resolution between the enantiomers peak was maintained acceptable throughout the small variations around the pH value of the buffer, different capillary, CE

instrument and electrolytes ion strength capacity, but changes in

concentration of cyclodextrins and acetonitrile showed significant effects on sepns. and affected the resolution. The validation results showed that the CE method

was suitable for separation of the racemic mixts. of the three glitazone drugs. The CE method was then applied for routine test during the drug and

formulation development work of balaglitazone. Due to the achieved results from this work, it is the authors' belief that this method can

easily sep. other glitazone racemic mixts.

IT 199113-98-9, Balaglitazone

RL: ANT (Analyte); ANST (Analytical study)

(generic, highly selective and robust capillary electrophoresis method

for separation of a racemic mixture of glitazone compds.)

L6 ANSWER 22 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2004:589248 HCAPLUS

DOCUMENT NUMBER: 141:140474

TITLE: Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds

SHER, Philip M.; Ellsworth, Bruce A.

SOURCE: U.S. Pat. Appl. Publ., 43 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004142938	A1	20040722	US 2003-712823	20031113
PRIORITY APPLN. INFO.:			US 2002-426465P	P 20021114
OTHER SOURCE(S):		MARPAT 141:140474		

GI



I



= W1



= W2




= W3

AB Prodrugs of glycogen phosphorylase inhibiting compds. are provided, said prodrug compds., G-(O2CR')m(OH)n(-O2C(CH2)pCH3)q (G = branched or straight C3-5-carbon chain and (-O2CR'), (-OH) and (-O2C(CH2)pCH3) are attached to any available carbon atom along G; m = 1 - 4; n = 0 - 3; p = 0 - 16; q = 0 - 3; where m + n + q = 3 or 4; and -O2CR' is a fragment of a compound I wherein W = W1, W2, W3; X = O, S, SO2, CHR5, , CHR5O, CHR5S, CHR5SO2, CHR5CO, CH2CHR5; Y = bond, CHR6; Z = aryl, heteroaryl; R1 = H, alkyl, alkenyl; R2 = H, alkyl, aryl, arylalkyl, heteroarylalkyl, alkenyl; R3, R4 = H, halo, CF3, CN, alkyl, alkoxy; R5, R6 = H, alkyl, aryl, alkenyl, CN, CH4R9A (tetrazole), CO2R9A, CONR9AR9B, CONR9AOR9B; A = CH, N; B = O, S; wherein R1, R2, R5, R6, R7, R8 = alkyl, aryl, alkenyl, arylalkyl, heteroarylalkyl, alkoxy, arylloxy and each may be substituted with 1 - 3 hydrogen bonding groups). Thus, 3-[(5-chloroindolecarbonyl)amino]-3,4-dihydrocarbostyryl I (R1 = R2 = H, W = 5-chloroindole, X = CH2, Y2 = benzo) was prepared from 3-amino-3,4-dihydrocarbostyryl via acylation with 5-chloroindolecarbonyl acid resin-bound 2,3,5,6-tetrafluorophenyl ester. Further provided are pharmaceutical compns. and methods for treating diabetes and related

L6 ANSWER 21 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

RN 199113-98-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

19

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 22 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

diseases employing compds. above, either alone or in combination with another therapeutic agent.

IT 199113-98-9, NN-2344

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(companion therapeutic agent (antidiabetic); preparation of triglyceride

and

triglyceride-like prodrugs of glycogen phosphorylase inhibiting compds.)

RN 199113-98-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 23 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:533962 HCAPLUS

DOCUMENT NUMBER: 141:82335

TITLE: Human glucagon-like-peptide-1 mimics and their antidiabetic effects
 INVENTOR(S): Natarajan, Sesha Iyer; Mapelli, Claudio; Bastos, Margarita M.; Bernatowicz, Michael; Lee, Ving; Ewing, William R.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 73 pp., Cont.-in-part of U.S. Ser. No. 273,975.
 CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004127423	A1	20040701	US 2003-419399	20030421
US 2003195157	A1	20031016	US 2002-273975	20021018
WO 2004094461	A2	20041104	WO 2004-US12374	20040421
WO 2004094461	A3	20050915		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1615653 A2 20060118 EP 2004-760098 20040421

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR


PRIORITY APPLN. INFO.: US 2001-342015P P 20011018
 US 2002-273975 A2 20021018
 US 2003-419399 A 20030421
 WO 2004-US12374 W 20040421

AB The invention discloses human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biol. activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the invention provides novel, chemical modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.

IT 199113-98-9, NN-2344
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (human glucagon-like-peptide-1 mimics and their antidiabetic effects)

RN 199113-98-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-

L6 ANSWER 23 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 quinazolinyl)methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:490736 HCAPLUS

DOCUMENT NUMBER: 141:47336

TITLE: Combination treatment for diabetes and related diseases using exendins and thiazolidinediones

INVENTOR(S): Knudsen, Lotte Bjerre

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050115	A2	20040617	WO 2003-DK824	20031201
WO 2004050115	A3	20040722		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003283216 A1 20040623 AU 2003-283216 20031201

EP 1569682 A2 20050907 EP 2003-775117 20031201

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

US 2004180824 A1 20040916 US 2003-726734 20031203

PRIORITY APPLN. INFO.: DK 2002-1864 A 20021203
 US 2002-431999P P 20021209
 WO 2003-DK824 W 20031201


AB The invention provides methods for treatment and/or prevention of diabetes and diabetes-related diseases. More specifically, the methods and uses of the invention pertain to administration of an exendin-4 compound in combination with administration of a thiazolidinedione insulin sensitizer.

IT 199113-98-9, 5-[[4-[(3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl)methoxy]phenyl)methyl]thiazolidine-2,4-dione
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (exendin-thiazolidinedione combination treatment for diabetes and related diseases)

RN 199113-98-9 HCAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004/037181	A2	2004/0506	WO 2003-US33385	2003/1021
WO 2004/037181	A3	2004/1021		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, SV, TJ, TM, TW, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BW, KE, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LV, MC, NL, PT, RO, SE, SI, SK, TR, BF, BF, CF, CG, CI, CM, GA, GN, QG, GW, ML, MR, NE, SN, TD, TG			
US 2004/259919	A1	2004/1223	US 2003-690173	2003/1021
US 6995180	B2	20060207		
EP 1553937	A2	20050720	EP 2003-774915	2003/1021
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MK, PT, IE, SI, LT, LV, FI, NO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY AGENCY. INFO.:			US 2002-420603P	P 2002/1023
			WO 2003-US33385	W 2003/1021
OTHER SOURCE(S): MARPAT 140:357672				
AB	Glycine nitrile derivs. R ¹ NHCH ₂ CH ₂ CH ₂ NR ² [R ¹ is H, alk(en)(ynyl) or (cyclo)alk(en)yl; R ² is (un)substituted alk(en)(yn)yl, (cyclo)alk(en)yl or arylalk(en)(yn)yl; R ³ is group given for R ² or cycloalkylalkyl, alkylthioalkyl, arylalkylthioalkyl, (hetero)aryl, heteroarylalkyl, cycloheteroalkyl or cycloheteroalkylalkyl, which may be substituted; R ⁴ is H or COMB or COMB with R ³ to form a 4- to 5-membered heterocyclic ring] were prepared for use in pharmaceutical compns. for the treatment of diabetes and related diseases. Thus, (S)-H ₂ NCH ₂ CH ₂ CH ₂ CONHCH ₂ CH ₂ CH ₂ was prepared by condensation of (S)-Boc-NHCH ₂ CH ₂ CO ₂ H (Boc = tert-butoxycarbonyl) with ENHCH ₂ CH ₂ (syntheses given), followed by deprotection using trifluoroacetic acid.			
IT	199113-98-9, NN-2344			
	RI: THU (Therapeutic use); BIOI (Biological study); USES (Uses) (antidiabetic agent; preparation of glycine nitrile amino acid derivs. as inhibitors of dipeptidyl peptidase IV)			
RN	199113-98-9 HCAPIUS			
CN	2,4-Thiazolidinedione, 5-[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl- (9CI) (CA INDEX NAME)			

L6 ANSWER 27 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L6 ANSWER 28 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:80450 HCAPLUS
 DOCUMENT NUMBER: 140:145835
 TITLE: Preparation of dibenzofused bicyclo[2.2.2]octane-derived amides as modulators of the glucocorticoid receptor
 INVENTOR(S): Vaccaro, Wayne; Yang, Bingwei Vera; Kim, Soong-hoon; Huynh, Tram; Tortolani, David R.; Leavitt, Kenneth J.; Li, Wenyi; Doweiko, Arthur M.; Chen, Xiao-tao; Doweiko, Lidia
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; et al.
 SOURCE: PCT Int. Appl., 265 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009017	A2	20040129	WO 2003-US22300	20030717
WO 2004009017	A3	20040708		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SJ, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004132759	A1	20040708	US 2003-621909	20030717
US 6995181	B2	20060207		
EP 1534273	A2	20050601	EP 2003-765638	20030717
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
NO 2005000074	A	20050309	NO 2005-74	20050106
US 2005171136	A1	20050804	US 2005-85347	20050321
PRIORITY APPLN. INFO.:				
			US 2002-396877P	P 20020718
			US 2003-621909	A1 20030717
			WO 2003-US22300	W 20030717
OTHER SOURCE(S): MARPAT 140:145835				
GI				

L6 ANSWER 28 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



II


AB Title compds. I [R-R4 = H, alk(en/yn)yl, alkoxy, aryl, etc.; Z = carboxamido, alkylamino, etc.] are prepared For instance, 2-amino-4,5-dimethylthiazole is coupled to the acid derived from the cycloaddn. of methacrylic acid and anthracene (CH3CN, EDCI, Et3N, HOAt, 18 h) to give II. I are glucocorticoid receptor modulators which are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, inflammatory and immune disorders.

IT 199113-98-9, NN 2344

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination pharmaceutical; preparation of dibenzofused bicyclo[2.2.2]octane-derived amides as modulators of glucocorticoid receptor)

RN 199113-98-9 HCAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 29 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:41231 HCAPLUS
 DOCUMENT NUMBER: 140:111429
 TITLE: Preparation of substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents
 INVENTOR(S): Chang, Peter T. W.; Chen, Sean; Devasthale, Pratik; Ding, Charles Z.; Herpin, Timothy F.; Wu, Shung; Zhang, Hao; Wang, Wei; Ye, Xiang-Yang
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 543 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004665	A2	20040115	WO 2003-US22149	20030702
WO 2004004665	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2005536494	T2	20051202	JP 2004-520148	20030702
US 2004063700	A1	20040401	US 2003-616365	20030708
NO 2005000077	A	20050203	NO 2005-77	20050106
PRIORITY APPLN. INFO.:				
			US 2002-394508P	P 20020709
			WO 2003-US22149	W 20030702
OTHER SOURCE(S): MARPAT 140:111429				
GI				



L6 ANSWER 29 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
halogen, (un)substituted amino, cyano; R3 = H, alkyl, arylalkyl, arylalkoxycarbonyl, alkylalkoxycarbonyl, alkynylalkoxycarbonyl, alkenylalkoxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, cycloheteroalkyl, etc.; E = CH, N; Z = (CH2)x5 (where x5 is 0, i.e. a single or a double bond, 1, 2), or Z is (CH2)x6 (where x6 = 2-5), where (CH2)x6 includes an alkenyl (C=C) bond embedded within the chain or Z = -(CH2)x7-O-(CH2)x8- (where x7, x8 = 0-4); (CH2)x to (CH2)x8, (CH2)m, (CH2)n, (CH2)p and (CH2)q may be optionally substituted; Y = CO2R4 (where R4 = H, alkyl, or a prodrug ester), or Y = a C-linked 1-tetrazole, a phosphonic acid of the structure P(O)(OR4a)R5 (where R4a = H, a prodrug ester; R5 = alkyl or aryl, or a phosphonic acid of the structure P(O)(OR4a)2] including all stereoisomers, prodrug esters, and pharmaceutically acceptable salts thereof are prepd. These compds., e.g. cis-1-ethoxycarbonyl-4-[3-[2-(2-phenyl-5-methylxazol-4-yl)ethoxy]phenyl]pyrrolidin-3-ylacetic acid and cis-1-[6-(trifluoromethyl)pyrimidin-2-yl]-4-[3-[2-(2-phenyl-5-methylxazol-4-yl)ethoxy]phenyl]pyrrolidine-3-carboxylic acid, modulate serum levels of blood glucose, triglyceride, insulin, and nonesterified fatty acid (NEFA) levels, and thus are particularly useful in the treatment of diabetes and obesity, esp. Type 2 diabetes, as well as hyperglycemia, hyperinsulinemia, hyperlipidemia, obesity, atherosclerosis, and related diseases employing such substituted acid derivs. alone or in combination with another antidiabetic agent and/or a hypolipidemic agent and/or other therapeutic agents. Disclosed is a method for treating diabetes, esp. Type 2 diabetes, and related diseases such as insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, inflammation, Syndrome X, diabetic complications, dysmetabolic syndrome, atherosclerosis, and related diseases, which comprises administering to a patient in need of treatment a therapeutically effective amt. of the compd. I. Also disclosed is a method for treating early malignant lesions (such as ductal carcinoma in situ of the breast and lobular carcinoma in situ of the breast), premalignant lesions including fibroadenoma of the breast and prostatic intraepithelial neoplasia (PIN), liposarcomas and various other epithelial tumors (including breast, prostate, colon, ovarian, gastric and lung), irritable bowel syndrome, Crohn's disease, gastric ulceritis, and osteoporosis and proliferative diseases such as psoriasis, which comprises administering to a patient in need of treatment a therapeutically effective amt. of the compd. I.

IT 199113-98-9, Balaglitazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of substituted heterocyclic derivs. as antidiabetic and antiobesity agents)


RN 199113-98-9 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 30 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:41224 HCAPLUS
DOCUMENT NUMBER: 140:111417
TITLE: Preparation of substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents
INVENTOR(S): Cheng, Peter T. W.; Chen, Sean; Ding, Charles Z.; Herpin, Timothy F.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004655	A2	20040115	WO 2003-US21331	20030708
WO 2004004655	A3	20041014		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2490972	AA	20040115	CA 2003-2490972	20030708
US 2004063762	A1	20040401	US 2003-616283	20030708
US 6875782	B2	20050405		
EP 1531810	A2	20050525	EP 2003-763345	20030708
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1665500	A	20050907	CN 2003-816038	20030708
JP 2006501187	T2	20060112	JP 2004-520018	20030708
NO 2004005529	A	20050203	NO 2004-5529	20041217
US 2005119312	A1	20050602	US 2004-16183	20041217
PRIORITY APPLN. INFO.:				
US 2002-394553P P 20020709				
US 2003-616283 A3 20030708				
WO 2003-US21331 W 20030708				

OTHER SOURCE(S): MARPAT 140:111417
GI




AB Compds. having general structure (I) [Q = C, N; A = (un)substituted (CH2)x (where x = 1-5) with an alkenyl bond or an alkynyl bond embedded anywhere]

L6 ANSWER 29 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


L6 ANSWER 30 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
in the chain, or A = (un)substituted -(CH2)x2-O-(CH2)x3- (where x2, x3 = 0-5, provided that at least one of x2 and x3 is other than 0); B = a bond, (un)substituted (CH2)x4 (where x4 = 1-5); X = CH, N; X2-X6 = C, N, O, or S, provided that at least one of X2-X6 is N; and at least one of X2, X3, X4, X5 and X6 is C; R1 = H, alkyl, R2, R2a, R2b, R2c = H, alkyl, alkoxy, halogen, (un)substituted amino, cyano; R3 = H, alkyl, arylalkyl, arylalkoxycarbonyl, alkylalkoxycarbonyl, alkynylalkoxycarbonyl, alkenylalkoxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, cycloheteroalkyl, heteroarylcarbonyl, heteroarylheteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, arylalkoxycarbonylamino, etc.; Y = CO2R (where R = H, alkyl, or a prodrug ester), or Y = a C-linked 1-tetrazole, a phosphonic acid of the structure P(O)(OR4a)R5 (where R4a = H, a prodrug ester; R5 = alkyl, aryl, or a phosphonic acid of the structure P(O)(OR4a)2] including all stereoisomers thereof, prodrug esters thereof, and pharmaceutically acceptable salts thereof are prepd. These compds. such as N-[[4-(1,2,3-triazol-4-ylmethoxy)benzyl](4-methoxyphenoxy)carbonyl]amino]acetic acid N-[[4-(2-(1,2,3-triazol-4-yl)ethoxy)benzyl](4-methoxyphenoxy)carbonyl]amino]acetic acid, N-[[1-[(4-(1,2,4-oxadiazol-3-ylmethoxy)phenyl]isopentyl](4-methoxyphenoxy)carbonyl]amino]acetic acid, N-[[1-[(4-(1,2,4-oxadiazol-3-ylmethoxy)phenyl]isopentyl](4-methoxyphenoxy)carbonyl]amino]acetic acid, N-[[4-(1,2,4-oxadiazol-3-ylmethoxy)phenethyl](isobutoxy)carbonyl]amino]acetic acid derivs. modulate serum levels of blood glucose, triglyceride, insulin, and nonesterified fatty acid (NEFA) and thus are particularly useful in the treatment of diabetes and obesity, esp. Type 2 diabetes, as well as hyperglycemia, hyperinsulinemia, hyperlipidemia, obesity, atherosclerosis, and related diseases.

IT 199113-98-9, Balaglitazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of substituted heterocyclic derivs. as antidiabetic and antiobesity agents)

RN 199113-98-9 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 31 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:3651 HCAPLUS
 DOCUMENT NUMBER: 140:73181
 TITLE: Lactam glycogen phosphorylase inhibitors and their use in disease treatment
 INVENTOR(S): Sher, Philip; Wu, Gang; Stouch, Terry; Ellsworth, Bruce
 PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 51 pp.
 SOURCE: CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:
 PATENT NO. KIND DATE APPLICATION NO. DATE
 US 2004002495 A1 20040101 US 2003-440851 20030519
 PRIORITY APPL. INFO.: US 2002-382002P P 20020520
 OTHER SOURCE(S): MARPAT 140:73181
 GI




AB Lactams I (W = bicyclic heteroaryl; X = O, S, SO₂, CHR₃, CHR₃O, CHR₃S, CHR₃SO₂, CHR₃CO, CH₂CHR₃; Y = bond, CHR₃; Z = aryl, heteroaryl; R₁ = H, alkyl, aryl, alkenyl; R₂ = H, alkyl, aryl, arylalkyl, heteroarylalkyl, alkenyl; R₃ = H, alkyl, aryl, alkenyl, CN, tetrazole derivative, CO₂R₄, CONR₄, CONR₄O₂; R₄ = H, alkyl, aryl, arylalkyl, heteroarylalkyl, etc.) which are glycogen phosphorylase inhibitors are disclosed. Further provided is a method for treating diabetes and related diseases employing a glycogen phosphorylase inhibiting amount of the above compound, either alone or in combination with another therapeutic agent. Thus, the syntheses of 3-(5-chloroindole-2-carbonylamino)-5-methoxy-3,4-dihydrocarboxystyryl and 3-(5-chloroindole-2-carbonylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-2-one, and numerous other related compounds, are described.
 IT 199113-98-9, NN 2344
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lactam glycogen phosphorylase inhibitors and)
 RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 32 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:757701 HCAPLUS
 DOCUMENT NUMBER: 139:281238
 TITLE: Novel crystalline form of 5-[[4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)methoxy]benzyl]thiazolidine-2,4-dione potassium salt
 INVENTOR(S): Potlappally, Rajender Kumar; Srisilla, Raju; Mamillapalli, Ramabhadra Sarma; Gaddam, Om Reddy
 PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:
 PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 2003078425 A1 20030925 WO 2003-1B935 20030314
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003209562 A1 20030929 AU 2003-209562 20030314
 EP 1487830 A1 20041222 EP 2003-744465 20030314
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005523300 T2 20050804 JP 2003-576430 20030314
 EP 1623984 A1 20060208 EP 2005-77388 20030314
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK
 US 2005234079 A1 20051020 US 2005-507399 20050613
 PRIORITY APPL. INFO.: IN 2002-MA180 A 20020315
 EP 2003-744465 A3 20030314
 WO 2003-1B935 W 20030314
 GI




AB The present invention relates to novel crystalline form of 5-[[4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)methoxy]benzyl]thiazolidine-2,4-dione potassium salt (I) and to a pharmaceutical composition comprising the novel

L6 ANSWER 31 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L6 ANSWER 32 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 cryst. form and a pharmaceutically acceptable carrier. The novel cryst. form of the present invention is more active, as an antidiabetic agent, than the hitherto known I. For example, a polymorphic Form I of I was prepd. by reacting 1.0 g of 5-[[4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)methoxy]benzyl]thiazolidine-2,4-dione dissolved in di-Et ketone at 75-80° with a methanolic soln. of potassium tert-butoxide (0.32 g) at 50-60°. The reaction mixt. was cooled to room temp. giving a ppt. after 3-4 h. The pptd. product was filtered, washed with di-Et ketone and vacuum dried to yield a polymorphic Form I of I (1.02 g).
 IT 199114-17-5P
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of crystalline form of potassium salt of quinazolinyl thiazolidinedione compound as antidiabetic agent)
 RN 199114-17-5 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-, potassium salt (9CI) (CA INDEX NAME)



● X

IT 199113-98-9
 RL: RCT (Reactant); RACT (Reactant or reagent) (preparation of crystalline form of potassium salt of quinazolinyl thiazolidinedione compound as antidiabetic agent)
 RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 33 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:65421 HCAPLUS
 DOCUMENT NUMBER: 139:197489
 TITLE: Preparation of azolecarboxylic acids useful as antidiabetic and antiobesity agents
 INVENTOR(S): Cheng, Peter T.; Zhang, Hao; Hariharan, Narayanan
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of U.S. Ser. No. 153,454.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003158232	A1	20030821	US 2002-294525	20021114
US 6967212	B2	20051122		20020522
US 2003092736	A1	20030515	US 2002-153454	20041215
US 2005124661	A1	20050609	US 2004-12810	20041215
PRIORITY APPLN. INFO.:			US 2001-294380P	P 20010530
			US 2002-153454	A2 20020522
			US 2002-294525	A3 20021114

OTHER SOURCE(S): MARPAT 139:197489
 GI



AB Title compds. [I: m, n = 0-2; Q = C, N; A = (CH2)x, (CH2)x1, (CH2)x20(CH2)x3; x = 1-5; x1 = 2-5; x2, x3 = 0-5; z1 of x2, x3 = 0; X1 = CH, N; X2, X3, X4, X5, X7 = C, N, O, S; in each of X1-X7, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b and R2c = H, alkyl, alkoxy, halo,


L6 ANSWER 34 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:320036 HCAPLUS
 DOCUMENT NUMBER: 138:338498
 TITLE: Preparation of human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
 INVENTOR(S): Natarajan, Sesha I.; Bastos, Margarita M.; Bernatowicz, Michael S.; Mapelli, Claudio; Lee, Ving; Ewing, William R.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 153 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003033671	A2	20030424	WO 2002-US33386	20021018
WO 2003033671	A3	20051229		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LX, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2463908	AA	20030424	CA 2002-2463908	20021018
JP 2005514337	T2	20050519	JP 2003-536401	20021018
EP 1572892	A2	20050914	EP 2002-782185	20021018
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
NO 2004001203	A	20040610	NO 2004-1203	20040323
ZA 2004002846	A	20050816	ZA 2004-2846	20040415
PRIORITY APPLN. INFO.:			US 2001-342015P	P 20011018
			WO 2002-US33386	W 20021018


OTHER SOURCE(S): MARPAT 138:338498

AB The invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics A-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Y-Z-B [Xaa1-Xaa9 are naturally or non-naturally occurring amino acid residues; Y and Z are amino acid residues which may be substituted; A and B are optionally present; A is H, an amino acid or peptide containing approx. 1-15 amino acid residues, an R group (H, (cyclo)alkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, (hetero)aryl, arylalkyl, aryloxyalkyl, heteroarylalkyl, or heteroaryloxyalkyl], an RCO (amide) group, a carbamate group, a urea, a sulfonamide, or an aminosulfonyl group; B is OH, alkoxy, etc., an amino or amino acid residue, or a peptide containing from 1-15 amino acid residues, terminating at the C-terminus as a carboxamide, ester, carbonyl, or an amino alc.] that mimic the biol. activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. These chemical-modified peptides stimulate insulin secretion in type II diabetics and produce other beneficial insulinotropic responses, while exhibiting increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. A method of preparing the polypeptides comprises replacing the message sequence of the polypeptide with a variant message sequence capable of inducing receptor mediated signal transduction. An

L6 ANSWER 33 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (substituted) amino; R3, R3a = H, alkyl, arylalkyl, aryloxyalkyl, alkylalkoxyalkyl, alkylalkoxyalkyl, alkenylalkoxyalkyl, arylalkoxyalkyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; with provisos], were prepd. as simultaneous inhibitors of peroxisome proliferator activated receptor-γ (PPARγ) and stimulators of peroxisome proliferator activated receptor-α (PPARα). Thus, title compd. (II) (prepd. starting from Meldrum's acid 3-methoxyphenylacetyl chloride) bound to human PPARα and to PPARγ ligand binding domains with IC50 = 69 nM.
 IT 199113-98-9
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (coadministration; preparation of azolecarboxylic acids useful as antidiabetic and antiobesity agents)
 RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 34 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 example is claimed peptide H-AEGTFTSD-Bip(2-Et)-Bip(2-Me)-NH2 (Bip = biphenylalanine residue).
 IT 199113-98-9
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (preparation of human glucagon-like-peptide-1 mimics for use in treatment of diabetes and related conditions)
 RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 35 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2003:202655 HCAPLUS

DOCUMENT NUMBER: 138:221784

TITLE: Preparation of O-pyrazole glucoside SGLT2 inhibitors as antidiabetic agents

INVENTOR(S): Washburn, William N.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020737	A1	20030313	WO 2002-US28480	20020905
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003087843	A1	20030508	US 2002-235336	20020905
EP 1432720	A1	20040630	EP 2002-761586	20020905
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
PRIORITY APPLN. INFO.:			US 2001-317280P	P 20010905
			WO 2002-US28480	W 20020905
OTHER SOURCE(S):			MARPAT 138:221784	

GI



AB O-pyrazole glucosides I, wherein A is CH₂ or (CH₂)₂; R₁ is hydrogen, arylalkyl, alkenyl, or alkyl; R₂ is alkyl or perfluoroalkyl; and R₃ and R₄

L6 ANSWER 36 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2003:77532 HCAPLUS

DOCUMENT NUMBER: 138:131130

TITLE: Combined use of derivatives of GLP-1 analogs and PPAR ligands

INVENTOR(S): Knudsen, Liselotte Bjerre; Wassermann, Karsten;

PATENT ASSIGNEE(S): Sturis, Jepper Brand, Christian Lehn

SOURCE: Den.

U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S.

Ser. No. 800,541.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003022816	A1	20030130	US 2001-949344	20010907
US 2003040469	A1	20030227	US 2001-800541	20010307
WO 2002069994	A2	20020912	WO 2002-DK142	20020307
WO 2002069994	A3	20030109		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1368055	A2	20031210	EP 2002-702232	20020307
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004518756	T2	20040624	JP 2002-569167	20020307
US 2005239707	A1	20051027	US 2005-146780	20050607
PRIORITY APPLN. INFO.:			US 2001-800541	A2 20010307
			DK 2000-375	A 20000308
			US 2000-191593P	P 20000320
			WO 2001-DK150	W 20010308
			DK 2001-812	A 20010521
			DK 2001-1315	A 20010907
			US 2001-949344	A 20010907
			DK 2001-1322	A 20010911
			US 2001-951300	A 20010913
			WO 2002-DK142	W 20020307

AB The invention provides methods and compns. for treatment and/or prevention of type 1 and type 2 diabetes, dyslipidemia, impaired glucose tolerance, insulin resistance, obesity, and beta-cell apoptosis, as well as methods for increasing the size and number of beta-cells in a subject and/or stimulating beta-cell proliferation, which comprise administering both a stable GLP-1 analog and a non-thiazolidinedione PPAR ligand.

IT 199113-98-9, 5-[[4-(3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl)methoxy]phenyl]methyl]thiazolidine-2,4-dione

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combined use of derivs. of GLP-1 analogs and PPAR ligands for treatment of diabetes and dyslipidemia)

RN 199113-98-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 35 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)


are independently hydrogen, OH, alkoxy, O-aryl, OCH₂-aryl, alkyl, cycloalkyl, CF₃, -OCHF₂, -3,4-(OCH₂)₂, -OCF₃, halogen, -CN, carboxylate, -CO₂H, acyl, amide, sulfonamide, Aryl, sulfide, sulfoxide; R₃ and R₄ together with the carbons to which they are attached form an annulated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, SO₂. Further provided are methods of using such compds. for the treatment of diabetes and related diseases, and to pharmaceutical compns. contg. such compds. Thus 1 (A = CH₂; R₁ = R₃ = R₄ = H; R₂ = Me) was prepd. as antidiabetic, anti-obesity, anti-hypertensive, anti-atherosclerotic, and lipid-lowering agent.

IT 199113-98-9

RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of O-pyrazole glucoside SGLT2 inhibitors as antidiabetic agents)

RN 199113-98-9 HCAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 36 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



L6 ANSWER 37 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2002:946995 HCAPLUS
 DOCUMENT NUMBER: 138:11429
 TITLE: Combined use of derivatives of GLP-1 analogs and PPAR ligands
 INVENTOR(S): Knudsen, Liselotte Bjerre; Wassermann, Karsten; Sturis, Jeppe; Brand, Christian Lehn Den.
 PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S. Ser. No. 800,541.
 SOURCE: CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002187926	A1	20021212	US 2001-951300	20010913
US 2003040469	A1	20030227	US 2001-800541	20010307
WO 2002069994	A2	20020912	WO 2002-DK142	20020307
WO 2002069994	A3	20030109		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1368055	A2	20031210	EP 2002-702232	20020307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004518756	T2	20040624	JP 2002-569167	20020307
US 2005239707	A1	20051027	US 2005-146780	20050607
PRIORITY APPLN. INFO.:				
			US 2001-800541	A2 20010307
			DK 2000-375	A 20000308
			US 2000-191593P	P 20000320
			WO 2001-DK150	W 20010308
			DK 2001-812	A 20010521
			DK 2001-1315	A 20010907
			US 2001-949344	A 20010907
			DK 2001-1322	A 20010911
			US 2001-951300	A 20010913
			WO 2002-DK142	W 20020307


AB The present invention relates to methods for treatment and/or prevention of type 1 diabetes, type 2 diabetes, dyslipidemia, impaired glucose tolerance, insulin resistance, obesity and beta-cell apoptosis, as well as methods for increasing the size and number of beta-cells in a subject and/or stimulating beta-cell proliferation. More specifically, the methods and uses of the invention pertain to administration of a stable derivative of a GLP-1 analog in combination with administration of a non-thiazolidinedione peroxisome proliferating activated receptor (PPAR) ligand. Treatment of diabetic rats with a combination of Arg34, Lys26(Ne-(γ-Glu(Na-hexadecanoyl))-GLP-1(7-37)) (50 μg/kg, twice daily) and (-)-2-ethoxy-3-(4-(2-phenoxazin-10-yl-ethoxy)-phenyl)-propionic acid (1

L6 ANSWER 38 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2002:927185 HCAPLUS
 DOCUMENT NUMBER: 138:24716
 TITLE: Preparation of azolecarboxylic acids useful as antidiabetic and antiobesity agents
 INVENTOR(S): Cheng, Peter T.; Zhang, Hao; Harikharan, Narayanan
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 169 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096358	A2	20021205	WO 2002-US16633	20020523
WO 2002096358	A3	20030327		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, PO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2449160	AA	20021205	CA 2002-2449160	20020523
EP 1390363	A2	20040225	EP 2002-729306	20020523
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
TR 200400650	T3	20040621	TR 2004-200400650	20020523
JP 2004536070	T2	20041202	JP 2002-592871	20020523
PRIORITY APPLN. INFO.:				
			US 2001-294380P	P 20010530
			WO 2002-US16633	W 20020523


OTHER SOURCE(S): MARPAT 138:24716
 GI

L6 ANSWER 37 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 mg/kg, once daily) had synergistic effects on HbA1c (glycosylated Hb) and 24-h glucose profiles.
 IT 199113-98-9, 5-[[4-(3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl)methoxy]phenyl]methyl-1-thiazolidine-2,4-dione
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combined use of derivs. of GLP-1 analogs and PPAR ligands for treatment of diabetes and dyslipidemia)
 RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 38 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)






ACCESSION NUMBER:	2002:927184	HCAPJWS
DOCUMENT NUMBER:	138:14048	
TITLE:	Preparation of oxazolythoxymethylphenylprolines and related compounds as antidiabetic and antibesity agents.	
INVENTOR(S):	Cheng, Peter T.; Jeon, Yoon; Wang, Wei	
PATENT ASSIGNEE(S):	Bristol-Myers Squibb Company, USA	
SOURCE:	FCT Int. Appl., 107 pp.	
	COOEN:	PIXXD2
DOCUMENT TYPE:	Patent	
LANGUAGE:	English	
FAMILY ACC. NUM. COUNT:	1	
PATENT INFORMATION:		

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096357	A2	20021205	WO 2002-US16628	20020523
US 2002096357	A3	20030925		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EE, EG, ES, FI, GB, GD, GE, GR, HK, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, HZ, SD, SL, SZ, TG, TZ, UG, ZM, AH, AZ, BY, BG, KB, KD, MD, T3, TD, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
US 2003092697	A1	20030515	US 2002-153342	20020522
CA 2449006	AA	20021205	CA 2002-2449006	20020523
EP 1401433	A2	20040211	EP 2002-737192	20020523
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2005050954		20050310	JP 2002-592870	20020523
PRIORITY PARENT INFO.:			US 2001-294505P	P 20010530
			WO 2002-US16628	W 20020523
OTHER SOURCE(S):	MARPAT	138:14048		
G1				




I



11

AB Title compds. [I = m, n = 0-2; Q = C, N; A = (CH₂)_m, (CH₂)_n], with an alkenyl or alkynyl bond in the chain, (CH₂)_xZO(CH₂)_y; x = 1-5; y = 1-5; Z = S, X₂ = C, N = O, S; X₃ = C, N; X₄ = C, N, O, S provided that ≥1 of X₂, X₃, X₄ = N in each of X₁-X₄. C may include CH; R¹ = H, alkyl; R² = H, alkyl, alkoxy, halo, (substituted) amino; R^{2a}, R^{2b} R^{2c} = H, alkyl, alkoxy, halo, (substituted) amino; R³ = H, alkyl, arylaalkyl, aryloxyacarbonyl, alklyoxyacarbonyl, alknyloxyocarbonyl, alkenyloxycarbonyl, arylocarbonyl, alkylcarbonyl, aryl, heteroaryl, cycloheteroalkyl, heteroarylacarbonyl, heteroarylheteroarylaalkyl, alkylcarbonylamino, arylocarbonylamino, heteroarylocarbonylamino, alkoxyacarbonylamino, aryloxyacarbonylamino, heteroaryloxyacarbonylamino, heteroarylheteroaryloxyacarbonylamino, alknylsulfonamido, aryloxyacarbonyl, cycloheteroalkyloxyacarbonyl, aryloxyheteroarylaalkyl, heteroarylaalkyloxyarylaalkyl, aryloxyalkyl, aryloxyalkenylarylaalkyl, aryloxyaminoarylaalkyl, etc.; Y = CO₂R⁴, 1-tetrazolyl, P(O)(OR^{4a})R⁵, P(O)(OR^{4a})₂; R⁴ = H, alkyl, prodrg ester; R^{4a} = H, prodrg ester; R⁵ = alkyl, aryl; Z = (CH₂)₄, (CH₂)₅, (CH₂)₆(CH₂)₇; x₄ = 1-5; x₅ = 2-5; w₆, x₇ = 0-4), were prepared as antidiabetic and antiobesity agents (n=2). Thus, title compound (II) was prepared in 6 steps.

IT 19913-98-9 HCN 234
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (coadministration; preparation of oxazolyethoxyphenylprolines and
 related
 compds. as antidiabetic and antiobesity agents)
 RN 19913-98-9 HCAPULP
 CN 2,4-Thiazolidinedione, 5-[[[3,4-dihydro-3-methyl-4-oxo-2-
 quinoxalinyl)methyl]phenyl]methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 40 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2002:81324 HCAPLUS

DOCUMENT NUMBER: 137:311200

TITLE: Preparation of 2,1-oxazoline and 1,2-pyrazoline-based

inhibitors of dipeptidyl peptidase IV

Sulsky, Richard B.; Robl, Jeffrey A.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083128	A1	20021024	WO 2002-US10936	20020405
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002183367	A1	20021205	US 2002-107279	20020326
US 6573287	B2	20030603		
CA 2444465	AA	20021024	CA 2002-2444465	20020405
EP 1377288	A1	20040107	EP 2002-723791	20020405
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004532220	T2	20041021	JP 2002-580932	20020405
PRIORITY APPLN. INFO.:			US 2001-283438P	P 20010412
			WO 2002-US10936	W 20020405

OTHER SOURCE(S): MARPAT 137:311200

GI



L6 ANSWER 41 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2002:813874 HCAPLUS

DOCUMENT NUMBER: 137:311199

TITLE: Amino acid complexes of C-aryl glucosides for

treatment of diabetes

Gougoutas, Jack Z.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083066	A2	20021024	WO 2002-US11066	20020408
WO 2002083066	A3	20030306		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2444481	AA	20021024	CA 2002-2444481	20020408
US 2003064935	A1	20030403	US 2002-117914	20020408
US 6774112	B2	20040810		
EP 1385856	A2	20040204	EP 2002-723801	20020408
EP 1385856	B1	20060222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004536047	T2	20041202	JP 2002-580871	20020408
PRIORITY APPLN. INFO.:			US 2001-283097P	P 20010411
			WO 2002-US11066	W 20020408

OTHER SOURCE(S): MARPAT 137:311199

GI



L6 ANSWER 42 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2002:793435 HCAPLUS
 DOCUMENT NUMBER: 137:289021
 TITLE: Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
 INVENTOR(S): Bussolari, Jacqueline C.; Chen, Xiaoli; Conway, Bruce R.; Demarest, Keith T.; Ross, Hamish N. M.; Severino, Rafael
 PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA
 SOURCE: PCT Int. Appl., 86 pp.
 CODEN: PIXKXD
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080936	A1	20021017	WO 2002-US10538	20020403
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2442917	AA	20021017	CA 2002-2442917	20020403
US 2003045553	A1	20030306	US 2002-115827	20020403
EP 1381361	A1	20040121	EP 2002-717766	20020403
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004529915	T2	20040930	JP 2002-578975	20020403
US 2003199557	A1	20031023	US 2003-395502	20030324
PRIORITY APPLN. INFO.:			US 2001-281429P	P 20010404
			US 2002-115827	A3 20020403
			WO 2002-US10538	W 20020403

AB Combination therapy comprising PPAR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.

IT 199113-98-9, Nn2344
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination therapy comprising glucose reabsorption inhibitors and PPAR modulators)

RN 199113-98-9 HCAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 43 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2002:736927 HCAPLUS
 DOCUMENT NUMBER: 137:247879
 TITLE: Preparation of antidiabetic agents C-aryl glucoside as human SGLT2 inhibitors
 INVENTOR(S): Ellsworth, Bruce; Washburn, William N.; Sher, Philip M.; Wu, Gang; Meng, Wei
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. 6,414,126.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002137903	A1	20020926	US 2002-151436	20020520
US 6515117	B2	20030204		
US 6414126	B1	20020702	US 2000-679027	20001004
ZA 200202604	A	20030703	ZA 2002-2604	20020403
CA 2486539	AA	20031204	CA 2003-2486539	20030515
WO 2003099836	A1	20031204	WO 2003-US15591	20030515
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003237886	A1	20031212	AU 2003-237886	20030515
EP 1506211	A1	20050216	EP 2003-736643	20030515
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011323	A	20050315	BR 2003-11323	20030515
JP 2005531588	T2	20051020	JP 2004-507493	20030515
NO 2004004915	A	20041216	NO 2004-4915	20041111
PRIORITY APPLN. INFO.:			US 1999-158773P	P 19991012
			US 2000-194615P	P 20000405
			US 2000-679027	A2 20001004
			US 2002-151436	A 20020520
			WO 2003-US15591	W 20030515


GI



I

AB An SGLT2 inhibiting compound is provided having the formula I method is also

L6 ANSWER 42 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 43 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

provided for treating diabetes and related diseases employing an SGLT2 inhibiting amt. of the above compd. alone or in combination with another antidiabetic agent or other therapeutic agent (no data). 1A pharmaceutical combination comprising an SGLT2 inhibitor compd. and an antidiabetic agent other than an SGLT2 inhibitor, for treating the complications of diabetes, an anti-obesity agent, an antihypertensive agent, an antiplatelet agent, an antiatherosclerotic agent, and/or a lipid-lowering agent (no data). A method for treating or delaying the progression or onset of diabetes, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis or hypertension, or for increasing high d. lipoprotein levels, which comprises administering to a mammalian species in need of treatment a therapeutically effective amt. of a compd (no data).

IT 199113-98-9, NN-2344
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of antidiabetic agents C-aryl glucosides as human SGLT2 inhibitors)

RN 199113-98-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 44 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:695802 HCAPLUS
 DOCUMENT NUMBER: 137:226618
 TITLE: Combined use of derivatives of GLP-1 analogs and PPAR ligands
 INVENTOR(S): Knudsen, Liselotte Bjerre; Wassermann, Karsten; Sturis, Jeppe; Brand, Christian Lehn; Godtfredsen, Carsten Foged
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
 SOURCE: PCT Int. Appl., 22 pp.
 CODEN: PIXMD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069994	A2	20020912	WO 2002-DK142	20020307
WO 2002069994	A3	20030109		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG			
US 2003040469	A1	20030227	US 2001-800541	20010307
WO 2001066135	A1	20010913	WO 2001-DK150	20010308
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG			
US 2003022816	A1	20030130	US 2001-949344	20010907
US 2002187926	A1	20021212	US 2001-951300	20010913
EP 1368055	A2	20031210	EP 2002-702232	20020307
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004518756	T2	20040624	JP 2002-569167	20020307
PRIORITY APPLN. INFO.:			US 2000-191593P	A 20000320
			US 2001-800541	A 20010307
			WO 2001-DK150	W 20010308
			DK 2001-812	A 20010521
			DK 2001-1315	A 20010907
			US 2001-949344	A 20010907
			DK 2001-1322	A 20010911
			US 2001-951300	A 20010913
			DK 2000-375	A 20000308
			WO 2002-DK142	W 20020307

AB The present invention relates to methods for treatment and/or prevention

L6 ANSWER 45 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:540258 HCAPLUS
 DOCUMENT NUMBER: 137:109267
 TITLE: Preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors
 INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 875,155.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002094977	A1	20020718	US 2001-7407	20011204
US 6627636	B2	20030930		
US 2002013334	A1	20020131	US 2001-875155	20010606
PRIORITY APPLN. INFO.:			US 2000-211595P	P 20000615
			US 2001-875155	A2 20010606


OTHER SOURCE(S): MARPAT 137:109267
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = O, S, SO, SO₂, NR₇; Z = HOCHCH₂CH(OH)CH₂CO₂R₃, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R₁, R₂ = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R₃ = H, alkyl, metal ion; R₄ = H, halo, CF₃, etc.; R₇ = H, alkyl, aryl, alkanoyl, aroyl, alkoxycarbonyl, etc.; R₉, R₁₀ = H, alkyl], were prepared as HMG CoA reductase inhibitors active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis (no data). A multistep synthesis of II is reported.

IT 199113-98-98, NN-2344
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)


RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 44 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 of type 1 diabetes, type 2 diabetes, dyslipidemia, impaired glucose tolerance, insulin resistance, obesity and beta-cell apoptosis. More specifically, the methods and uses of the invention pertain to administration of a stable deriv. of a GLP-1 analog in combination with administration of a non-thiazolidinedione peroxisome proliferating activated receptor (PPAR) ligand. Treatment of diabetic rats with a combination of Arg34,Lys26(Ne-(γ-Glu(Na-hexadecanoyl))-GLP-1(7-37)) (50 μg/kg, twice daily) and (-)-2-ethoxy-3-(4-(2-phenoxazin-10-yl-ethoxy)-phenyl)-propionic acid (1 mg/kg, once daily) had synergistic effects on HbA_{1c} and 24-h glucose profiles.

IT 199113-98-9
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combined use of derivs. of GLP-1 analogs and PPAR ligands for treatment of diabetes and dyslipidemia)

RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 45 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L6 ANSWER 46 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:392237 HCAPLUS
 DOCUMENT NUMBER: 136:401651
 TITLE: Preparation of fused pyridine derivatives as HMG-CoA reductase inhibitors
 INVENTOR(S): Robt, Jeffrey A.; Chen, Bang-Chi; Sun, Chong-Qing
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 875,218.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002061901	A1	20020523	US 2001-8154	20011204
US 6620821	B2	20030916		
US 2002028826	A1	20020307	US 2001-875218	20010606
US 2004024216	A1	20040205	US 2003-602753	20030624
PRIORITY APPLN. INFO.:			US 2000-211594P	P 20000615
			US 2001-875218	A2 20010606
			US 2001-8154	A3 20011204

OTHER SOURCE(S): MARPAT 136:401651
 GI



AB The title compds. I and their pharmaceutically acceptable salts, esters, prodrug esters, and stereoisomers are claimed [wherein: Z = CH(OH)CH2CR7(OH)CH2CO2R3 or corresponding pyranone lactone derivs.; n = 0, 1; x = 0, 1, 2, 3, or 4; y = 0, 1, 2, 3, or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of (CH2)x and/or (CH2)y together with addnl. carbons form a 3 to 7 membered spirocyclic ring; R1, R2 = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R3 = H or lower alkyl; R4 = H, halo, CF3, OH, alkyl, alkoxy, CO2H, (un)substituted NH2, cyano, (un)substituted CONH2, etc.; R7 = H, alkyl]. The compds. are HMG-CoA reductase inhibitors, and are active in inhibiting cholesterol biosynthesis and modulating blood serum lipids, for example, lowering LDL

L6 ANSWER 47 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:885761 HCAPLUS
 DOCUMENT NUMBER: 136:11208
 TITLE: Pharmaceutical compositions containing dihydroquinazolinylthiadiazolidinedione derivative
 INVENTOR(S): Weibel, Heller Hjorth, Thyge Borup
 PATENT ASSIGNEE(S): Novo Nordisk A/S; Den.; Reddy's Research Foundation
 SOURCE: PCT Int. Appl., 19 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001091751	A1	20011206	WO 2000-DK291	20000530
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000049111	A5	20011211	AU 2000-49111	20000530
WO 2001089523	A1	20011129	WO 2001-DK348	20010521
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001060083	A5	20011203	AU 2001-60083	20010521
EP 1303273	A1	20030423	EP 2001-933644	20010521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004506609	T2	20040304	JP 2001-585767	20010521
US 2002010187	A1	20020124	US 2001-863986	20010523
US 6710050	B2	20040323		
US 2004091523	A1	20040513	US 2003-699043	20031031
PRIORITY APPLN. INFO.:			US 2000-207889P	P 20000525
			US 2000-578887	A 20000526
			US 2000-207777P	P 20000530
			WO 2000-DK291	A 20000530
			WO 2001-DK348	W 20010521
			US 2001-863986	A1 20010523

AB The present invention provides a new stable pharmaceutical composition containing 5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl]methyl]thiadiazolidine-2,4-dione (I) as active ingredient. Thus, tablets contained I potassium salt 9, microcryst. cellulose 20, lactose 66, Mg stearate 0.5, and talc 4.51.
 IT 199113-98-9 199114-17-5
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical compns. containing dihydroquinazolinylthiadiazolidinedione

L6 ANSWER 46 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 cholesterol and/or increasing HDL cholesterol (no data). I are thus useful in treating hyperlipidemia and dyslipidemia, in hormone replacement therapy, and in treating hypercholesterolemia, hypertriglyceridemia and atherosclerosis, as well as Alzheimer's disease and osteoporosis. Preps. of several compds. are described. For instance, a multistep synthesis of fused pyridine deriv. II is reported. Compds. I may be used in a manner similar to atorvastatin, pravastatin, simvastatin, etc. Combinations of compds. I with various other drugs are claimed, the latter being specified as certain pharmacol. classes, as inhibitors of specific enzymes, as (ant)agonists of specific receptors, and as numerous named drugs.
 IT 199113-98-9, NN-2344


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (therapeutic compns. also containing; preparation of fused pyridine derivs. as HMG-CoA reductase inhibitors)

RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 47 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 199114-17-5 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-, potassium salt (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 48 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:86222 HCAPLUS

DOCUMENT NUMBER: 136:11151

TITLE: New pharmaceutical composition containing quinazolinylmethoxyphenylmethyl thiazolidinone and the process for its preparation

INVENTOR(S): Weibel, Helle; Hjorth, Thyge Borup

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Reddy's Research Foundation

SOURCE: PCT Int. Appl., 20 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001089523	A1	20011129	WO 2001-DK348	20010521
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001091751	A1	20011206	WO 2000-DK291	20000530
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001060083	A5	20011203	AU 2001-60083	20010521
EP 1303273	A1	20030423	EP 2001-933644	20010521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004506609	T2	20040304	JP 2001-585767	20010521
PRIORITY APPLN. INFO.: US 2000-578887 A 20000526				
US 2000-207777P F 20000530				
WO 2000-DK291 A 20000530				
WO 2001-DK348 W 20010521				

AB The present invention provides a new stable pharmaceutical composition containing 5-[[4-([3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl)methoxy]phenyl)methyl]thiazolidine-2,4-dione (I) as active ingredient useful in the treatment of type 2 diabetes. A tablet contained 19, microcryst. cellulose 20, lactose 66, magnesium stearate 0.5, and talc 4.5%.

IT 199113-98-9 199114-17-5

RL: THU (Therapeutic use): BIOL (Biological study): USES (Uses) (new pharmaceutical composition containing quinazolinylmethoxyphenyl thiazolidinone and process for its preparation)

RN 199113-98-9 HCAPLUS

L6 ANSWER 49 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:809089 HCAPLUS

DOCUMENT NUMBER: 135:344476

TITLE: Preparation of substituted thiazolidinediones having antidiabetic, hypolipidemic and antihypertensive properties

INVENTOR(S): Lohray, Vidya Bhushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema; Ramanujam, Rajagopalan; Chakrabarti, Ranjan

PATENT ASSIGNEE(S): Reddy-Cheminar, Inc., USA; Reddy's Research Foundation

SOURCE: U.S., 26 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6313113	B1	20011106	US 1997-982911	19971202
WO 9845291	A1	19981015	WO 1998-US7284	19980410
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9871097	A1	19981030	AU 1998-71097	19980410
EP 1036075	A1	20000920	EP 1998-918108	19980410
EP 1036075	B1	20040623		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002510283	T2	20020402	JP 1998-543172	19980410
AT 269862	E	20040715	AT 1998-918108	19980410
US 6030973	A	20000229	US 1998-135566	19980617
PRIORITY APPLN. INFO.: IN 1997-HA771 A 19970415				
US 1997-982911 A 19971202				
WO 1998-US7284 W 19980410				

OTHER SOURCE(S): MARPAT 135:344476


GI



AB The title compds. [I: X = O, S; R1-R4 = H, halo, OH, etc.; W = O, S, (un)substituted NH; R5 = H, OH, halo, etc.; R6 = H, alkyl, cycloalkyl.


L6 ANSWER 48 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN 2,4-Thiazolidinedione, 5-[[4-([3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl)methyl]-, potassium salt (9CI) (CA INDEX NAME)



RN 199114-17-5 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-([3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl)methyl]-, potassium salt (9CI) (CA INDEX NAME)



● K

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 49 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


etc.; n = 1-4; Ar = (un)substituted divalent (hetero)arom. group; R7, R8 = H, halo, OH, etc.; B = O, S, were prep. and formulated. Thus, cyclization of N-methylanthranilamide with 5-[[4-([2,2-dithoxy]ethoxy]phenyl)methyl]thiazolidine-2,4-dione (prepn. given) afforded 44% [X = O; R1-R5, R7, R8 = H; W = NH; R6 = Me; n = 1; Ar = 1,4-phenylene; B = S] which showed 55% max. redn. in blood glucose level and 35% triglyceride lowering activity.

IT 199113-98-7 199113-98-9

RL: RCT (Reactant): RACT (Reactant or reagent) (preparation and pharmacol. activity of benzoquinazolinonyl- and benzoxazinonylmethoxybenzylthiazolidinediones)


RN 199113-98-7 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-([3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 199113-98-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-([3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 50 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:792332 HCAPLUS

DOCUMENT NUMBER: 135:331438

TITLE: Preparation of heterocyclic compounds for the treatment of diabetes and related diseases
 INVENTOR(S): Lohray, Vidya Bhushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema; Gurram, Ranga Madhavan; Ramanujam, Rajagopalan; Chakrabarti, Ranjan; Pakala, Sarna K. S.

PATENT ASSIGNEE(S): Reddy's Research Foundation, India; Reddy-Cheminor Inc.

SOURCE: U.S., 35 pp., Cont.-in-part of U.S. 5,985,884.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6310069	B1	20011030	US 2000-535387	20000324
US 5885997	A	19990323	US 1996-777627	19961231
US 5985884	A	19991116	US 1997-884816	19970630
			US 1996-777627	A2 19961231
			US 1997-884816	A2 19970630
			IN 1996-MA1150	A 19960701

OTHER SOURCE(S): MARPAT 135:331438

GI




AB The title compds. [I; one of X, Y, Z = C(O), C(S) and one of the remaining of X, Y, Z = C or C:; R1-R3 = H, halo, OH, etc.; n = 1-4; Ar = (un)substituted divalent aryl, heteroaryl; R4 = H, halo, alkyl or forms a bond together with the adjacent group A; A = N, CR5 (wherein R5 = H, halo,

L6 ANSWER 50 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 199114-15-3 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6,7-dimethoxy-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)




IT 199113-91-2P 199113-99-0P 199114-04-0P
 199114-16-4P 199114-17-5P 199114-18-6P
 199114-19-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclic compds. for the treatment of diabetes and related diseases)


RN 199113-91-2 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxyphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 199113-99-0 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 199114-04-0 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-, sodium salt (9CI) (CA INDEX NAME)

L6 ANSWER 50 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

alkyl or R5 forms a bond together with R4); B = O, S when A = CR5 and B = O when A = N], novel antidiabetic compds., were prepd. and formulated. Thus, reacting 4-[2-(2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl)ethoxy]benzaldehyde (prepn. given) with thiazolidine-2,4-dione afforded II which showed 67% max. redn. in blood glucose level at 100 mg/kg/day (6 days treatment) in mice.


IT 199113-88-7P 199113-89-8P 199113-98-9P

199114-15-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of heterocyclic compds. for the treatment of diabetes and related diseases)


RN 199113-88-7 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)




RN 199113-89-8 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)



RN 199113-98-9 HCAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 50 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 199114-16-4 HCAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6,7-dimethoxy-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 199114-17-5 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-, potassium salt (9CI) (CA INDEX NAME)




● K

RN 199114-18-6 HCAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-, calcium salt (9CI) (CA INDEX NAME)

L6 ANSWER 50 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 1/2 Ca


RN 199114-19-7 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]-, sodium salt (9CI) (CA INDEX NAME)



● Na

REFERENCE COUNT: 95 THERE ARE 95 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 51 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




II

AB Comps. of formula I [wherein: n is 1-5; X is N or CR5, where R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl group; R1 is H, alk(en)ynyl, alk(enyl)ynyl, alkoxy, (aryl)3Si, cycloalk(en)yl, (aryl)amino, aryl(alkyl), cycloheteroaryl, etc.; R2, R3 and R4 are any of the groups set out for R1 and optionally substituted with 1 to 5 substituents which may be the same or different and when X is N, R1 is preferably aryl or heteroaryl] are claimed. Several hundred examples are disclosed. Synthesis of II proceeds via cyclopropanation of the cinnamate derived from the olefination between 3,5-dichlorobenzaldehyde and t-butylideneethylphosphonoacetate. The intermediate tert-Bu ester is converted to the corresponding α-chloroketone and reacted with acetyl guanidine to provide II in a total of 5 steps. Comps. I are said to be sodium/proton exchange inhibitors (NHIE). Pharmaceutical combinations are claimed using I and certain antihypertensive agents, β-adrenergic agonists, hypolipidemic agents, antidiabetic agents, antiobesity agents, etc. Comps. I are useful as antianginal and cardioprotective agents and provide a method for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia.

IT 199113-98-9, NN 2344
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceuticals also containing: synthesis and use of heterocyclic sodium/proton exchange inhibitors)

RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)



L6 ANSWER 51 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN



ACCESSION NUMBER: 2001:283949 HCAPLUS
 DOCUMENT NUMBER: 134:311218
 TITLE: Synthesis and use of heterocyclic sodium/proton exchange inhibitors
 INVENTOR(S): Ahmad, Saleem; Wu, Shung C.; O'Neil, Steven V.; Ngu, Khehyong; Atwal, Karnail S.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 221 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027107	A2	20010419	WO 2000-US27461	20001002
WO 2001027107	A3	20020124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6887870	B1	20050503	US 2000-669298	20000925
CA 2388813	AA	20010419	CA 2000-2388813	20001002
EP 1224183	A2	20020724	EP 2000-968723	20001002
EP 1224183	B1	20051228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000014725	A	20030617	BR 2000-14725	20001002
JP 2003527331	T2	20030916	JP 2001-530325	20001002
NZ 517668	A	20040924	NZ 2000-517668	20001002
AT 314364	E	20060115	AT 2000-968723	20001002
ZA 2002002479	A	20040727	ZA 2002-2479	20020327
NO 2002001717	A	20020610	NO 2002-1717	20020411
US 2005137216	A1	20050623	US 2005-46993	20050131
PRIORITY APPLN. INFO.:			US 1999-158755P	P 19991012
			US 2000-669298	A3 20000925
			WO 2000-US27461	W 20001002
OTHER SOURCE(S):		MARPAT 134:311218		
GI				

L6 ANSWER 52 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:208280 HCAPLUS
 DOCUMENT NUMBER: 134:252328
 TITLE: Preparation of 2-(oxalylamino)-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acids as protein tyrosine phosphatase inhibitors
 INVENTOR(S): Andersen, Henrik Sune; Hansen, Thomas Kruse; Lau, Jesper; Moller, Niels Peter Hundahl; Olsen, Ole Hvilsted; Ake, Frank Urban; Ge, Yu; Holsworth, Daniel Dale; Jones, Todd Kevin; Judge, Luke Milburn; Ripka, William Charles; Shapira, Barry Zvi; Uyeda, Roy Teruyuki
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.: Ontogen Corporation
 SOURCE: PCT Int. Appl., 147 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019831	A1	20010322	WO 2000-DK503	20000911
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1214325	A1	20020619	EP 2000-958277	20000911
EP 1214325	B1	20051109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 200309430	T2	20030311	JP 2001-523408	20000911
AT 309250	E	20051115	AT 2000-958277	20000911
PRIORITY APPLN. INFO.:			DK 1999-1278	A 19990910
			WO 2000-DK503	W 20000911
OTHER SOURCE(S):		MARPAT 134:252328		
GI				




AB The title compds. (I) [wherein n = 0-2; m = 1 or 2; X = S or O; Y = O, S, SO, or SO₂; R₁ = H or CO₂R₃, tetrazolyl, 3-hydroxyoxazolyl, 3-hydroxyisothiazolyl, 3-hydroxypyrazolyl, 3-hydroxy-1,2,4-oxadiazolyl, 2-thio-1,3,4-oxadiazolyl, 2-hydroxyoxazolyl, 2-hydroxythiazolyl, etc.; R₂ = H, alkyl, OH, or NR₇R₈; R₃ = H (ar)alkyl, or alkylcarbonyloxy(ar)alkyl; R₄-R₆ = independently H, trihalomethyl, (ar)alkyl, (hetero)aryl, OH, oxo, carbonyl(alkyl), alkylcarbonyl, alkoxy(alkyl), (ar)alkyloxyalkyl, thio, alkylthio, (un)substituted amino, acyl, alkylcarbonylamino(alkyl), etc.; R₇ and R₈ = independently H, (ar)alkyl, aryl, (ar)alkylcarbonyl, arylcarbonyl, or (ar)alkylcarbonyl; or R₇ and R₈ together with the N to which they are attached form an (un)substituted mono-, bi-, or tricyclic ring system containing 0-3 heteroatoms; or R₇ and R₈ = independently a 5-7 membered amine, imide, or lactam] were prepared as inhibitors of protein tyrosine phosphatases (PTPases), such as PTP1B, CD45, SHP-1, SHP-2, PTPn, LAR, and HePTP. For example, 5-(4-benzoyloxy-1,3-dioxo-1,3-dihydroindol-2-ylmethyl)-2-(tert-butoxyoxalylamino)-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid tert Bu ester was debenzylated using Pd/C in EtOAc (67%) and deesterified using 25% TFA in CH₂Cl₂ to afford II (72%). In a study evaluating for biol. activity against a truncated form of PTP1B, II inhibited PTP1B with a K_i of 1.5 μM. I are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases (no data).

IT 199113-98-9, 5-[[4-[(3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl)methoxy]phenyl]methyl]thiazolidine-2,4-dione

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (insulin sensitizer; combination therapy comprising insulin sensitizers and 2-(oxalylamino)-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid PTP1B inhibitors)

RN 199113-98-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:208279 HCAPLUS

DOCUMENT NUMBER: 134:252327

TITLE: Preparation of 2-(oxalylamino)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acids as protein tyrosine phosphatase inhibitors

INVENTOR(S): Andersen, Henrik Sune; Hansen, Thomas Kruse; Lau, Jesper; Moller, Niels Peter Hundahl; Olsen, Ole Hvilsted; Ake, Frank Urban; Ge, Yu; Holsworth, Daniel Dale; Jones, Todd Kevin; Judge, Luke Milburn; Ripka, William Charles; Shapira, Barry Zvi; Uyeda, Roy Tecuyuki

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Ontogen Corp.

SOURCE: PCT Int. Appl., 150 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019830	A1	20010322	WO 2000-DK502	20000911
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TW, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1214324	A1	20020619	EP 2000-958276	20000911
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
US 6410556	B1	20020625	US 2000-659547	20000911
JP 2003509429	T2	20030311	JP 2001-523407	20000911
PRIORITY APPLN. INFO.:				
			DK 1999-1277	A 19990910
			DK 2000-1069	A 20000707
			US 1999-156742P	P 19990930
			WO 2000-DK502	W 20000911

OTHER SOURCE(S): MARPAT 134:252327

GI



AB The title compds. (I) [wherein n = 0-2; m = 1 or 2; X = S or O; Y = O, S, SO, or SO₂; R₁ = H or CO₂R₃, tetrazolyl, 3-hydroxyoxazolyl, 3-hydroxyisothiazolyl, 3-hydroxypyrazolyl, 3-hydroxy-1,2,4-oxadiazolyl, 2-thio-1,3,4-oxadiazolyl, 2-hydroxyoxazolyl, 2-hydroxythiazolyl, etc.; R₂ = H, alkyl, OH, or NR₇R₈; R₃ = H (ar)alkyl, or alkylcarbonyloxy(ar)alkyl; R₄-R₆ = independently H, trihalomethyl, (ar)alkyl, (hetero)aryl, OH, oxo, carbonyl(alkyl), alkylcarbonyl, alkoxy(alkyl), (ar)alkyloxyalkyl, thio, alkylthio, (un)substituted amino, acyl, alkylcarbonylamino(alkyl), etc.; R₇ and R₈ = independently H, (ar)alkyl, aryl, (ar)alkylcarbonyl, arylcarbonyl, or (ar)alkylcarbonyl; or R₇ and R₈ together with the N to which they are attached form an (un)substituted mono-, bi-, or tricyclic ring system containing 0-3 heteroatoms; or R₇ and R₈ = independently a 5-7 membered amine, imide, or lactam] were prepared as inhibitors of protein tyrosine phosphatases (PTPases), such as PTP1B, CD45, SHP-1, SHP-2, PTPn, LAR, and HePTP. For example, reaction of 2-bromomethyl-3-methoxymethoxybenzoic acid Me ester (preparation given) with 2-amino-5-aminomethyl-6-(4-methoxybenzyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid tert-Bu ester, amidation using imidazol-1-yloxoacetic acid tert-Bu ester, debenzylation using Pd/C and 10% formic acid in MeOH, and deesterification with 30% TFA afforded II=H₂N⁺ (90%). In a study evaluating for biol. activity against a truncated form of PTP1B, II inhibited PTP1B with a K_i of 250 nM. I are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases (no data).


IT 199113-98-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (insulin sensitizer; combination therapy comprising insulin sensitizers and 2-(oxalylamino)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid PTP1B inhibitors)

RN 199113-98-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 53 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 54 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:185561 HCAPLUS

DOCUMENT NUMBER: 134:237465

TITLE: Method of inhibiting protein tyrosine phosphatases with an aspartic acid residue at position 48
 INVENTOR(S): Andersen, Henrik Sune; Hansen, Thomas Kruse; Iverson, Lars Fogh; Lau, Jesper; Moller, Niels Peter Hundahl; Olsen, Ole Hvilsted; Ake, Frank Urban; Ge, Yu; Holsworth, Daniel Dale; Jones, Todd Kevin; Judge, Luke Milburn; Ripka, William Charles; Shapira, Barry Zvi; Uyeda, Roy Teruyuki

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Ontogen Corp.
 SOURCE: PCT Int. Appl., 644 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001017516	A2	20010315	WO 2000-US24761	20000911
WO 2001017516	A3	20011108		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1214060	A2	20020619	EP 2000-963340	20000911
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPLM. INFO.: DK 1999-1279 A 19990910				
US 1999-156641P P 19990929				
WO 2000-US24761 W 20000911				

GI

L6 ANSWER 54 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The present invention provides a method of inhibiting protein tyrosine phosphatases (PTPases, PTPs), such as PTP1B, TC-PTP, CD45, SHP-1, PTPa, PTPb, PTPc, PTPd, PTPe, PTPf, PTPg, PTPh, PTPi, and PTP-LAR, by administration of compds. which have structural, phys., and spatial characteristics that allow them to interact with an aspartic acid residue at position 48 of PTP1B and/or TC-PTP. Prepn. for over 100 thieno[2,3-c]pyridines and thieno[2,3-c]pyridines (I) [wherein n = 0-2; m = 0-2; and m = n ≥ 1; X = S, O, NR8; Y = NR9, O, S, SO, SO2; R1 = H, CO2R3, or a 5-membered heterocycle such as tetrazolyl, 3-hydroxyisoxazolyl, 3-hydroxyisothiazolyl, 3-hydroxypyrazolyl, 2-(hydroxy or thio)-1,3,4-oxadiazolyl, 2-oxoimidazolyl, etc.; R2 = H, alkyl, OH, or NR9R10; R3 = H, (ar)alkyl, or alkylcarbonyloxy(ar)alkyl; R4 - R6 = independently H, trihalomethyl, (ar)alkyl, aryl, OH, oxo, CO2H, carboxyalkyl, (ar)alkyloxycarbonyl, alkylaminoalkyl, (ar)alkylcarbonylamino, etc.; R8 - R10 = independently H or (un)substituted (ar)alkyl, aryl, (ar)alkylcarbonyl, arylcarbonyl, or (ar)alkylcarboxy; or R9 and R10 together with the N to which they are attached form an (un)substituted cyclic, bicyclic, or tricyclic ring system containing 0-3 heteroatoms; or R9 and R10 = independently a 5-7 membered cyclic amine, imide, or lactam] and structural-based PTPase inhibition data are included. For example, 5-(4-benzoyloxy-1,3-dioxo-1,3-dihydroisindol-2-ylmethyl)-2-(tert-butoxycarbonylamino)-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid tert-Bu ester was debenzoylated using Pd/C and treated with 25% TFA in CH2Cl2 to give II. II showed potency against PTP1B, PTPa D1, PTPb D1, PTPc, PTPd, and CD45 D1D2 with Ki values (μM) of 1.9, 93, 11, 1.1, and 130, resp. I are indicated in the management or treatment of a broad range of diseases such as autoimmune diseases, acute and chronic inflammation, osteoporosis, various forms of cancer and malignant diseases, and type I diabetes and type II diabetes (no data). In addition, I are useful in the isolation of PTPases and in elucidation of their biol. function.


IT 199113-90-9, 5-[[4-[[[3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl]methyl]thiazolidine-2,4-dione
 RI: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (insulin sensitizer; compns. containing insulin sensitizers and selective inhibitors of protein tyrosine phosphatases)

RN 199113-90-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[[[3,4-dihydro-3-methyl-4-oxo-2-

L6 ANSWER 54 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

quinazolinyl]methoxy]phenyl]methyl)-(9CI) (CA INDEX NAME)



L6 ANSWER 55 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:383924 HCAPLUS

DOCUMENT NUMBER: 133:3424

TITLE: New pharmaceutical composition containing thiazolidine derivatives for the treatment of type-2 diabetes

INVENTOR(S): Weibel, Helle; Hjorth, Thyge Borup

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Reddy's Research Foundation

SOURCE: PCT Int. Appl., 20 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032191	A1	20000608	WO 1999-DK663	19991129
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2352430	AA	20000608	CA 1999-2352430	19991129
BR 9915835	A	20010821	BR 1999-15835	19991129
EP 1135127	A1	20010926	EP 1999-972919	19991129
EP 1135127	B1	20060125		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
JP 2002531404	T2	20020924	JP 2000-584886	19991129
RU 2233659	C2	20040810	RU 2001-117850	19991129
AU 776299	B2	20040902	AU 2000-13762	19991129
ZA 2001004261	A	20020524	ZA 2001-4261	20010531
NO 2001002673	A	20010531	NO 2001-2673	20010531
PRIORITY APPLM. INFO.:			DK 1998-1580	A 19981201
			WO 1999-DK663	W 19991129

AB The present invention provides a new stable pharmaceutical composition containing

5-[[4-[(3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl)methoxy]phenyl-methyl]thiazolidine-2,4-dione (I) as active ingredient for the treatment of type-2 diabetes. A tablet contained 1 potassium salt 9, microcryst. cellulose 20, lactose 66, magnesium stearate 0.5, and talc 4.54.

IT 199113-98-9 199114-17-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(new pharmaceutical composition containing thiazolidine derivs. for treatment of type-2 diabetes)

RN 199113-98-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 56 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:191085 HCAPLUS

DOCUMENT NUMBER: 132:222546

TITLE: An improved process for the preparation of thiazolidine-2,4-dione derivatives

INVENTOR(S): Chebiyyam, Prabhakar; Poelapally, Rajender Kumar; Gade, Chinnna Bakki Reddy; Satish, Balaram Mahanti; Mamillapalli, Ramabhadra Sarmar; Gaddam, Om Reddy

PATENT ASSIGNEE(S): Reddy's Research Foundation, India

SOURCE: PCT Int. Appl., 49 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000015638	A1	20000323	WO 1999-IB1530	19990910
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IN 187716	A	20020615	IN 1998-MA2060	19980914
CA 2343883	AA	20000323	CA 1999-2343883	19990910
AU 9954399	A1	20000403	AU 1999-54399	19990910
AU 762353	B2	20030626		
BR 9914493	A	20010626	BR 1999-14493	19990910
EP 1114047	A1	20010711	EP 1999-940422	19990910
EP 1114047	B1	20030319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002524563	T2	20020806	JP 2000-570176	19990910
NZ 510316	A	20021126	NZ 1999-510316	19990910
AT 234834	E	20030415	AT 1999-940422	19990910
PT 1114047	T	20030731	PT 1999-940422	19990910
ES 2195600	T3	20031201	ES 1999-940422	19990910
RU 2223961	C2	20040220	RU 2001-110171	19990910
IN 189187	A	20030104	IN 1999-MA1150	19991129
ZA 2001001699	A	20020528	ZA 2001-1699	20010228
NO 2001001265	A	20010514	NO 2001-1265	20010313
NO 2001001265	B1	20041018		
US 6469167	B1	20021022	US 2001-763940	20010502
PRIORITY APPLM. INFO.:			IN 1998-MA2060	A 19980914
			WO 1999-IB1530	W 19990910


OTHER SOURCE(S): CASREACT 132:222546; MARPAT 132:222546

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title compound 5-[[4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)methoxy]benzyl]thiazolidine-2,4-dione (I), useful as antidiabetic agent (no data), was prepared by reducing the compound II (R = alkyl) over Raney Ni

L6 ANSWER 55 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 199114-17-5 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-, potassium salt (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 56 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

or Mg in Cl-4 alc. or mixts. thereof, if desired reesterifying using H2SO4 at a temp. 0-60°, hydrolyzing the resulting compd. III, and condensing the acid IV with N-Me anthranilamide directly without any preactivation, and if desired, converting the compd. I to pharmaceutically acceptable salts thereof by conventional methods.


IT 199113-98-9P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(an improved process for the preparation of thiazolidine-2,4-dione derivs.)

RN 199113-98-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




IT 199114-17-5P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(an improved process for the preparation of thiazolidine-2,4-dione derivs.)

RN 199114-17-5 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-, potassium salt (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 57 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 1999-733038 HCAPLUS

DOCUMENT NUMBER: 131.351343

TITLE: Preparation of heterocyclic compounds for the treatment of diabetes and related diseases
 INVENTOR(S): Lohray, Vidya Bhushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema; Gurram, Ranga Madhavan; Ramanujam, Rajagopalan; Chakrabarti, Ranjan; Pakala, Sarma K. S.

PATENT ASSIGNEE(S): Reddy's Research Foundation, India; Reddy-Cheminar Inc.
 SOURCE: U.S., 35 pp., Cont.-in-part of U.S. 5,885,997.

CODEN: USXXAM
 DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5985884	A	19991116	US 1997-884816	19970630
US 5885997	A	19990323	US 1996-777627	19961231
US 6114526	A	20000905	US 1999-353286	19990714
US 6310069	B1	20011030	US 2000-535387	20000324
US 6573268	B1	20030603	US 2000-535388	20000324
US 2001031759	A1	20011018	US 2001-827009	20010405
US 6372750	B2	20020416		
US 2002123502	A1	20020905	US 2001-32846	20011226
US 6780992	B2	20040824		
US 2005032864	A1	20050210	US 2004-917221	20040812
PRIORITY APPLN. INFO.:			IN 1996-MA1150	A 19960701
			US 1996-777627	A2 19961231
			US 1997-884816	A 19970630
			US 1999-353286	A3 19990714
			US 2000-535388	A3 20000324
			US 2001-827009	A3 20010405
			US 2001-32846	A1 20011226

OTHER SOURCE(S): HARPAT 131:351343

GI

L6 ANSWER 57 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB The title compds. [I; one of X, Y, Z = C(O), C(S) and one of the remaining of X, Y, Z = C and the other C; R1-R3 = H, halo, OH, etc.; n = 1-4; Ar = (un)substituted divalent aryl, heteroaryl; R4 = H, halo, alkyl or forms a bond together with the adjacent group A; A = N, CR5 (wherein R5 = H, halo, alkyl or R5 forms a bond together with R4); B = O, S when A = CR5 and B = O when A = N], novel antidiabetic compds., were prepared and formulated. Thus, reacting 4-[2-(2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl)ethoxy]benzaldehyde (preparation given) with thiazolidine-2,4-dione afforded II which showed 67% maximum reduction in blood glucose level at 100 mg/kg/day (6 days treatment) in mice.


IT 199113-88-7P 199113-89-8P 199113-98-9P

199114-15-3P

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

RN 199113-88-7 HCAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)



L6 ANSWER 57 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)


RN 199113-89-8 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)




RN 199113-98-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)



RN 199114-15-3 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6,7-dimethoxy-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)



IT 199113-91-2P 199113-99-0P 199114-04-0P

199114-16-4P 199114-17-5P 199114-18-6P


199114-19-7P

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

RN 199113-91-2 HCAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxyphenyl]methylene]- (9CI) (CA INDEX NAME)

L6 ANSWER 57 OF 60 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 199113-99-0 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)



RN 199114-04-0 HCAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]-, sodium salt (9CI) (CA INDEX NAME)



● Na


RN 199114-16-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6,7-dimethoxy-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]-, sodium salt (9CI) (CA INDEX NAME)




● Na

L6 ANSWER 57 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 199114-17-5 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-, potassium salt (9CI) (CA INDEX NAME)




● K

RN 199114-18-6 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-, calcium salt (9CI) (CA INDEX NAME)



● 1/2 Ca

RN 199114-19-7 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]-, sodium salt (9CI) (CA INDEX NAME)



● Na

L6 ANSWER 58 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:212642 HCAPLUS
 DOCUMENT NUMBER: 130:223293
 TITLE: Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
 INVENTOR(S): Lohray, Vidya Bhushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema
 PATENT ASSIGNEE(S): Reddy's Research Foundation, India; Reddy-Cheminor, Inc.
 SOURCE: U.S., 26 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5885997	A	19990323	US 1996-777627	19961231
CA 2258949	AA	19971106	CA 1997-2258949	19970630
WO 9741097	A2	19971106	WO 1997-US11522	19970630
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9737198	A1	19971119	AU 1997-37198	19970630
AU 744518	B2	20020228		
US 5985884	A	19991116	US 1997-884816	19970630
EP 958296	A1	19991124	EP 1997-934041	19970630
EP 958296	B1	20030730		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
BR 9711098	A	20000308	BR 1997-11098	19970630
CN 1275982	A	20001206	CN 1997-195778	19970630
JP 2002515874	T2	20020528	JP 1997-539307	19970630
IL 127296	A1	20030112	IL 1997-127296	19970630
RU 2200161	C2	20030310	RU 1998-123195	19970630
AT 246190	E	20030815	AT 1997-934041	19970630
PT 958296	T	20031128	PT 1997-934041	19970630
ES 2199366	T3	20040216	ES 1997-934041	19970630
IL 142649	A1	20041215	IL 1997-142649	19970630
ZA 9705866	A	19980223	ZA 1997-5866	19970701
MX 9810782	A	20001130	MX 1998-10782	19981215
NO 9806055	A	19981222	NO 1998-6055	19981222
NO 313699	B1	20021118		
US 6114526	A	20000905	US 1999-353286	19990714
US 6310069	B1	20011030	US 2000-535387	20000324
US 6573268	B1	20030603	US 2000-535388	20000324
RX 1026204	A1	20050121	RX 2000-103109	20000524
US 2001031759	A1	20011018	US 2001-827009	20010405
US 6372750	B2	20020416		
US 2002123502	A1	20020905	US 2001-32846	20011226
US 6780992	B2	20040824		
US 2005032864	A1	20050210	US 2004-917221	20040812
PRIORITY APPLN. INFO.:				
			IN 1996-MA1150	A 19960701
			US 1996-777627	A 19961231

L6 ANSWER 57 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 REFERENCE COUNT: 84
 THERE ARE 84 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 58 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IL 1997-127296 A3 19970630
 US 1997-884816 A 19970630
 WO 1997-US11522 W 19970630
 US 1999-353286 A3 19990714
 US 2000-535388 A3 20000324
 US 2001-827009 A3 20010405
 US 2001-32846 A1 20011226

OTHER SOURCE(S): MARPAT 130:223293
 GI



AB The present invention relates to novel antidiabetic compds., their tautomeric forms, their derivs., their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compns. containing them. This invention particularly relates to novel azolidinedione derivs., and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically compns. containing them. Approx. 30 title compds. such


as I (R = Pr, Me, Et, Bu, benzyl) and their quinazoline analogs were prepared in 66-99% yields, e.g., by condensation of aldehydes II with thiazolidine-2,4-dione. Antidiabetic data was given for several of the prepared compds. At 30 mg/kg/day, after 6 days,

5-[4-[2-[2-ethyl-4-methyl-6-oxo-1,5-dihydro-1-pyrimidinyl]ethoxy]phenylmethyl] thiazolidine-2,4-dione reduced the blood glucose level 73%, lowered triglycerides 70% and also lowered cholesterol in the rat.


IT 199113-88-7P 199113-89-8P 199113-98-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation of pyrimidinylethoxybenzylthiazolidinediones)

RN 199113-88-7 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)


L6 ANSWER 58 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 199113-89-8 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)



RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT 199113-91-2P 199113-99-0P 199114-04-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of pyrimidinylethoxybenzylthiazolidinediones)
 RN 199113-91-2 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxyphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 199113-99-0 HCAPLUS


L6 ANSWER 59 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:682388 HCAPLUS
 DOCUMENT NUMBER: 129:290130
 TITLE: Substituted thiazolidinediones having antidiabetic, hypolipidemia and antihypertensive properties
 LOHray, Vidya Bhushan; LOHray, Braj Bhushan;
 INVENTOR(S): Paraselli, Rao Bheema; Ramanujam, Rajagopalan;
 Chakrabarti, Ranjan
 PATENT ASSIGNEE(S): Reddy's Research Foundation, India; Reddy-Cheminor Inc.
 SOURCE: PCT Int. Appl., 75 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9845291	A1	19981015	WO 1998-US7284	19980410
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, CA, GN, ML, MR, NE, SN, TD, TG			
US 6313113	B1	20011106	US 1997-982911	19971202
AU 9871097	A1	19981030	AU 1998-71097	19980410
EP 1036075	A1	20000920	EP 1998-918108	19980410
EP 1036075	B1	20040623		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002510283	T2	20020402	JP 1998-543172	19980410
AT 269862	E	20040715	AT 1998-918108	19980410
PRIORITY APPLN. INFO.:			US 1997-982911	A 19971202
			IN 1997-MK771	A 19970415
			WO 1998-US7284	W 19980410

OTHER SOURCE(S): MARPAT 129:290130
 GI

L6 ANSWER 58 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2,4-Thiazolidinedione, 5-[[4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 199114-04-0 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na


REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 59 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Title compds. such as I (R = H, Me, Et; X = O, NR1; R1 = H, Me, Et) were prepared in 23-82% yields by cyclization of o-HXC6H4CONH2 with acetals such as II.

IT 199113-88-7 199113-98-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation and pharmacol. activity of benzoquinazolinonyl- and benzoxazinonylmethoxybenzylthiazolidinediones)
 RN 199113-88-7 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)



RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 59 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L6 ANSWER 60 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:740205 HCAPLUS
 DOCUMENT NUMBER: 128:13282
 TITLE: Preparation of thiazolidinediones and analogs as antidiabetics
 INVENTOR(S): Lohray, Vidya Bhushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema; Gurram, Ranga Madhavan; Ramanujam, Rajagopalan; Chakrabarti, Ranjan; Pakala, Sarma K. S.
 PATENT ASSIGNEE(S): Dr. Reddy's Research Foundation, India;
 SOURCE: PCT Int. Appl., 112 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741097	A2	19971106	WO 1997-US11522	19970630
W:	AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5885997	A	19990323	US 1996-777627	19961231
AU 9737198	A1	19971119	AU 1997-37198	19970630
AU 744518	B2	20020228		
EP 958296	A1	19991124	EP 1997-934041	19970630
EP 958296	B1	20030730		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI			
BR 9711098	A	20000308	BR 1997-11098	19970630
JP 2002515874	T2	20020528	JP 1997-539307	19970630
IL 127296	A1	20030112	IL 1997-127296	19970630
RU 2200161	C2	20030310	RU 1998-123195	19970630
AT 246190	E	20030815	AT 1997-934041	19970630
IL 142649	A1	20041215	IL 1997-142649	19970630
MX 9810782	A	20001130	MX 1998-10782	19981215
NO 9806055	A	19981222	NO 1998-6055	19981222
NO 313699	B1	20021118		
HK 1026204	A1	20050121	HK 2000-103109	20000524
PRIORITY APPLN. INFO.:			US 1996-777627	A 19961231
			IN 1996-M1150	A 19960701
			IL 1997-127296	A3 19970630
			WO 1997-US11522	W 19970630
OTHER SOURCE(S):	MARPAT 128:13282			
GI				

L6 ANSWER 60 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Title compds. [I: A = N, CR5: B = O or S; R = CHR42O(CH2)nR1; R1 = (un)substituted pyrimidinyl, -quinazolinyl, etc.; R4,R5 = H, halo, alkyl; R4R5 = bonds; Z = divalent aromatic or heterocyclic group; n = 1-4] were prepared. Thus, 4-methyl-2-propyl-1,6-dihydro-6-pyrimidinone was N-alkylated by 4-(BrCH2CH2O)C6H4CHO and the product condensed with thiazolidine-2,4-dione to give, after hydrogenation, title compound II.


IT Data for biol. activity of I were given.
 199113-88-7P 199113-89-8P 199113-91-2P
 199113-98-9P 199113-99-0P 199114-04-0P
 199114-15-3P 199114-16-4P 199114-17-5P
 199114-18-6P 199114-19-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 199113-88-7 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)




RN 199113-88-8 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)




RN 199113-91-2 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxyphenyl]methylene]- (9CI) (CA INDEX NAME)


L6 ANSWER 60 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 199113-98-9 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)



RN 199113-99-0 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)




RN 199114-04-0 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 199114-15-3 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6,7-dimethoxy-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)

L6 ANSWER 60 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 199114-16-4 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6,7-dimethoxy-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na


RN 199114-17-5 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-, potassium salt (9CI) (CA INDEX NAME)



● X


RN 199114-18-6 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-, calcium salt (9CI) (CA INDEX NAME)

L6 ANSWER 60 OF 60 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 1/2 Ca

RN 199114-19-7 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methylene]-, sodium salt (9CI) (CA INDEX NAME)



● Na